Help - Search - Members - Calendar
Full Version: Today's Research
HealthCastle.com Community > Health Castle Forums > Food Science Forum
Pages: 1, 2
John Bobbin BNat
Hi Everyone,
After looking at several of the posts that have appeared on here recently, highlighting pseudo-science I thought it was time to put some real science on here. Naturopaths have always considered garlic beneficial for heart conditions. Researchers now believe they have found how it reduces high blood pressure and relaxes heart muscle, similarly to nitric oxide.

http://ajpheart.physiology.org/cgi/content/full/292/4/H1953

Coenzyme Q10 has also been shown to be effective in hypertension.

Coenzyme Q 10 in the treatment of hypertension: a meta-analysis of the clinical trials - all 5 versions »
http://scholar.google.com/scholar?hl=en&am...amp;oi=scholarr

You can also accept Glucosamine as a proven treatment for Osteoarthritis

http://www.anta.com.au/PDF%20Files/Osteoar...is%20Thesis.pdf

Glucosamine is also a good treatment for inflammation as it indirectly increases apoptosis of activated white blood cells by reducing the "stay alive signal" secreted by T helper cells, which reduces general inflammation.

http://www.jleukbio.org/cgi/content/full/71/4/632

Curcumin is also a good anti-inflammatory where there is chronic obstructive pulmonary diseases such as emphysema or chronic bronchitis and sepsis is involved.

http://www.ccmjournal.com/pt/re/ccm/abstra...sionid=LGhZ0YyF
Cheers biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Bitter Melon will become a patented medicine ( or at least extracts from it) for Diabetes mellitus 2 after this ground breaking research.


Chemistry & Biology
Switch Journal

* Home
* Search
* Archive
* Subscribe
* Feedback

* Email Alerts
* RSS
* Help
* Jobs
* Cell Press

RegisterLoginPasswordAuto-LoginPassword Reminder
Title/abstract/keywords Author Volume First Page
Click here!

Copyright © 2008 Cell Press. All rights reserved.
Chemistry and Biology, Vol 15, 263-273, 21 March 2008
Article
Antidiabetic Activities of Triterpenoids Isolated from Bitter Melon Associated with Activation of the AMPK Pathway

Min-Jia Tan,1,5 Ji-Ming Ye,2,5 Nigel Turner,2,5 Cordula Hohnen-Behrens,2 Chang-Qiang Ke,1 Chun-Ping Tang,1 Tong Chen,1 Hans-Christoph Weiss,3 Ernst-Rudolf Gesing,4 Alex Rowland,2 David E. James,2, and Yang Ye1,

1 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China
2 Diabetes and Obesity Research Program, Garvan Institute of Medical Research, University of New South Wales, Sydney, NSW 2010, Australia
3 Bayer Industry Services GmbH & Co., Leverkusen 51368, Germany
4 Bayer CropScience AG, R & D, Agricultural Center, Monheim 40789, Germany

Corresponding author
David E. James
d.james@garvan.org.au

Corresponding author
Yang Ye
yye@mail.shcnc.ac.cn

Summary

Four cucurbitane glycosides, momordicosides Q, R, S, and T, and stereochemistry-established karaviloside XI, were isolated from the vegetable bitter melon (Momordica charantia). These compounds and their aglycones exhibited a number of biologic effects beneficial to diabetes and obesity. In both L6 myotubes and 3T3-L1 adipocytes, they stimulated GLUT4 translocation to the cell membrane—an essential step for inducible glucose entry into cells. This was associated with increased activity of AMP-activated protein kinase (AMPK), a key pathway mediating glucose uptake and fatty acid oxidation. Furthermore, momordicoside(s) enhanced fatty acid oxidation and glucose disposal during glucose tolerance tests in both insulin-sensitive and insulin-resistant mice. These findings indicate that cucurbitane triterpenoids, the characteristic constituents of M. charantia, may provide leads as a class of therapeutics for diabetes and obesity.

rolleyes.gif rolleyes.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Not all natural products are safe for everyone, in the Journal of Complementary Medicine ( Australia's most prestigious integrative medicine journal) May/June 2008 page 10 there is another case of Black Cohosh causing total destruction of a 51 year old woman of European descent's liver. This lady had been taking Black Cohosh at a dose of 20 Mgs per day for 3 years for menopausal problems, but 2 months before the onset of symptoms she doubled the dose to counteract severe menopausal symptoms, this was double the recommended dosage. She had no family history of liver problems, she did not consume alcohol, she was not taking any other medication or illicit drugs. She was admitted to the Flinders Medical Centre in Adelaide SA with acute hepatitis and after 62 days she suffered liver failure and had to have a liver transplant. So far about 9 cases of liver failure have been reported world wide due to Black Cohosh. Be careful of taking natural medicine, remember if it can do you good it can also do you harm when abused.
Cheers unsure.gif dry.gif sad.gif unsure.gif
John Bobbin BNat
Hi Readers,
Here is an interesting one, Glucosamine has been used for osteoarthritis since 1995 over here in Oz, I was using it a bit earlier, 1993 for myself and a couple of sports people in the area. Glucosamine certainly worked for me and these other people from the sporting clubs, I haven't felt pain in my ankles from osteoarthritis since I started to take it back then right up until now, but the researchers have decided that it is only placebo effect that we are feeling, and Glucosamine does nothing to alleviate pain. unsure.gif unsure.gif unsure.gif
Cheers
My meta -analysis for my Bachelor Degree was accepted after peer reviewing also.

http://www.anta.com.au/PDF%20Files/Osteoar...is%20Thesis.pdf
John Bobbin BNat
Hi Readers,
Helicobacter pylori causes ulcers ( no question about this) and these ulcers frequently turn to cancer when left untreated, so it is good to see complementary medicine products being able to eradicate H.pylori.
The complementary medicine products are Cranberry juice and Lactobacillus johnsonii, read on .
http://www.google.com.au/search?source=ig&...earch&meta=.

In case this does not work here's the link.
GottelandM Andrews M, Toledo M. et al. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1

Cheers biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Do you suffer from atopic dermatitis (AD), well if you do easing the problem may be as simple as eating more fatty fish, research published in the Journal of Complementary Medicine, Koch C,et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema. British Journal of Dermatology 2008;158:786-92
At the end of 20 weeks, significant reduction in severity scoring of AD scores were observed in the DHA group but not in the placebo group.
Cheers biggrin.gif biggrin.gif
John Bobbin BNat
Hi Everyone,
More good news for complementary medicine Spirulina has been shown to lower serum lipids and blood pressure in a new trial at the National Autonomous University of Mexico. At the end of the 6 week trial subjects (16 males and 20 females) were found to have a 40% decrease in total cholesterol and a decrease of 10mmHg systolic and 8mmHg for males and for females 11mmHg systolic and 6mmHg diastolic, that is a good result.

Policosanols
I don't always get time to do this so I write as much as I can each time.
Policosanol has failed again , researchers from the University of Padua (Italy) confirmed that an 8 week trial using 68 subjects (mean age 53 years) found no effect on lipids at the end of the study, in fact I think the only time Policosanols have been found to lower lipids was in the original research done in Cuba, where they extracted Policosanols from sugarcane.
Cheers
John Bobbin BNat
Hi Everyone
The American Institute for Cancer Research is warning people not to look to supplements to prevent cancer.

http://www.aicr.org/site/News2?abbr=pr_&am...le&id=13094

Cheers unsure.gif unsure.gif
John Bobbin BNat
Hi Readers,
Research from various sites are literally yelling at people to eat more fibre (fruit and vegetables), eat more garlic and move (exercise) to protect themselves against colorectal cancer. From the research it seems that colorectal cancer would be the easiest cancer to prevent with more lifestyle and dietary modifications open to us. Don't drink alcohol every day or if you do make sure you don't drink more than 2 standard drinks male or female. Avoid processed meat such as salami, bacon, ham, sausage or hot dogs, only eat any of these on special occasions. Don't eat anything preserved with smoking,salting, curing or any food that has used chemicals for this purpose. Vegetables also contain phytochemicals which researchers believe probably protects us from this cancer. If you had one parent develop colorectal cancer your lifetime risk goes from 2% to 6% and if they got it before the age of 45 your risk goes to 15% and if both parents got it your risk goes up to 16% according to the National Cancer Institute. If you barbecue avoid flame flare ups that burn the meat, and remember only 18 ozs of redmeat (lamb,pork,beef) per week. People older than 50 years should be checked by their GP.

Cheers biggrin.gif biggrin.gif
John Bobbin BNat
Hi Everyone.
Research from Cell Metabolism and published in PubMed has shown how peoples hunger is increased or even initiated by visual cues, a hormone called Ghrelin creates hunger and is also one of the pleasure hormones stimulating the pleasure regions of the brain. So you have dual causes of hunger and this may be part of the reason so many people have difficulties with weight loss, they know they have to eat less but there are too many visual cues exciting their brains pleasure regions.

http://www.ncbi.nlm.nih.gov/pubmed/1846033...Entrez.Pubmed.P

Cheers biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
I have just finished listening to a segment of "Naked Scientist" which arrived last week 21/5/08 on podcast.
One of the trials the scientists spoke about intrigued me a lot, they are using parasitology to fight allergies.
According to the scientists at Nottingham University allergic response came about because we wanted to expel worms, the worms devised some tactics to stop us expelling them by switching off our allergic response, and now the scientists want to turn that back on the worms. By ingesting 10 worms in a dose until they reach 25, which they have identified as the optimal number by measuring the number of worms carried around by villagers in New Guinea, they think they will be able to stop Rhinorrhea (Hay Fever) and Crohn's Disease.
The Nottingham scientists are working on hay fever and an Australian University is working on Crohn's.
How interesting is that, using the parasites that created the problem in the first place to cure it in the second instance.

Cheers biggrin.gif biggrin.gif tongue.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Today's front page audio on Omega 3's by Gloria and Evelyn I found intriguing, I have never seen any science on the conversion of ALA to DHA and this forum talks a lot about flaxseed.In Australia we don't eat much if any Flaxseed, and I haven't ever heard anyone speak of it as a major contribution to their diet. I have always thought that any plant conversions would be less than the formed version as in Iron etc.Today I spent some time searching for research that was meaningful and I think I finally found some, read this.


Conversion Efficiency of ALA to DHA in Humans

A discussion of the metabolic pathway by which dietary ALA can be converted by a series of sequential desaturation (D) and elongation (E) reactions into EPA and then DHA in the mammalian liver was provided in the metabolism of omega-3 and omega-3 section. This multi-step sequence is briefly outlined below:
ALA - precursor
( 18:3n -3) (D insertion of unsaturation

18:4n-3

20:4n-3 E(+2 carbons)
D
- accumulation in heart and other tissue cells
EPA
20.4n-3

EPA ( fish/fish oil E
functional foods) DHA 22:5n-3

24:5n-3 E

24:6n-3 D

DHA (-2 carbons)
(22:6n-3) End product- accumulation in brain, retina, heart and other tissues


The pioneering rodent studies, reported by Lamptey and Walker in 1976 and subsequently supported in numerous subsequent experimental studies, showed that omega-3 deprivation impaired the learning ability of young animals and that rats could convert ALA into DHA for assimilation into brain tissue (membrane phospholipid components). These rodent-based studies had a significant influence on official recommendations from Health and Welfare Canada (1990) and the Food and Nutrition Board (2002) wherein dietary ALA and not DHA, the brain/retina omega-3 fatty acid for structure-functioning, was recognized as the only essential dietary fatty acid. Official recommended minimal intakes were established for ALA for all members of the population (young and old alike). However, extensive controlled studies in human subjects have now all consistently confirmed the very limited metabolic conversion of dietary ALA into DHA, the final end product of the sequential pathway.

A common approach for assessing the apparent conversion efficiency of dietary ALA to the longer-chain products (EPA plus DHA) in controlled human trials is to determine the net mass rise in circulating (blood) levels of EPA and DHA after increasing the dietary intake of ALA from food sources. The early studies in 1993 conducted at the University of Manitoba in collaboration with the University of Guelph in Canada involved 42-day phases of feeding controlled diets with markedly different levels of omega-3 fatty acid as ALA (alpha-linolenic acid) along with varying amounts of omega-6 fatty acid as LA (linoleic acid) and varying omega-6:omega-3 ratios. While some moderate net rise in the level of EPA (eicosapentaenoic acid) was found with higher levels of ALA in conjunction with omega-6:omega-3 ratios lowered to 3:1; no net rise in the level of circulating DHA was found across the various fatty acid mixtures and ratios. This early evidence for a very limited conversion of dietary ALA into DHA has been supported subsequently by other controlled studies in humans using mass measurements. For example, the feeding of 10.7 grams (10,700 mg) of ALA from flaxseed oil over a four week period failed to provide any significant net rise in the low levels of DHA present in the breast milk of lactating women. It is noteworthy that the levels of ALA supplementation used in the latter study from the Oregon Health and Science University (by Francois et al.) was approximately seven-fold that recommended for pregnant recommended by Health and Welfare Canada (1990) and by the Food and Nutrition Board (2002) during pregnancy.

The availability of ALA labeled with stable isotopes, which avoid potential biological hazards associated with the use of radio-isotopes in human studies, has allowed detailed and sophisticated investigations of the metabolic conversion efficiency of ALA to EPA and DHA. This technology has been utilized and reported upon in a number of recent studies in medical and nutrition journals. The original study using this technology was reported from the U.S. Department of Agriculture in 1994 wherein the conversion efficiency of ALA to DHA in young adult male subjects was reported to be at the level of a 4% efficiency, which would predict that 25 parts of dietary ALA would be needed to provide the equivalent rise in circulating levels of DHA which could be delivered by the direct consumption of one part of DHA. The overall conversion efficiency from ALA to EPA plus DHA combined was estimated to be 12%. It is noteworthy that the very limited conversion of ALA to DHA was also highly variable between the individual subjects thereby indicating difficulty in predicting those in the population who may have extremely compromised capacities for the conversion of ALA to DHA. Subsequent studies by Pawlosky et al. (2001) using similar technology and that more recently by Hussein et al. (2005) showed estimated conversions from ALA to DHA of less than 0.1% and a conversion to EPA plus DHA combined of less than 0.4% efficiency overall. The latter study was conducted over a fairly lengthy time period of 12-weeks in duration. Burgee et al. from the U.K. has compared the apparent conversion efficiency of ALA to DHA in young adult men and women. Interestingly, no detectable formation of DHA was found in the men whereas an approximate conversion efficiency from ALA to DHA of 9% was found in women. These authors suggest that the greater fractional conversion in women may be due in part to a significantly lower rate of utilization of dietary ALA for beta-oxidation and/or the influence of estrogen or other hormonal factors on the conversion efficiency. In summary, the conversion efficiency from ALA to DHA is very limited in healthy individuals; furthermore, the apparent inefficiency of the conversion from ALA to DHA is markedly variable between individuals within different sectors of the populations such that the lack of sufficient dietary DHA could compromise optimal health in those with very minimal conversion capacities. The very low conversion efficiencies and wide variation in capacities lend support to serious consideration being given to dietary DHA as an 'essential' fatty acid and/or a 'conditionally essential' fatty acid depending upon the conversion capacity of individuals within the population.

Burdge, G.C., and Calder, P.C. Conversion of a-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod. Nutr. Dev. 45: 581-597, 2005.

Burdge, G.C., and Wootton , S.A. Conversion of a-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Brit. J. Nutr. 88: 411-420, 2002.

Burdge, G.C., et al. Eicosapentaenoic and docosahexaenoic acids are the principle products of alpha-linolenic acid metabolism inyoung men. Brit. J. Nutr. 88: 355-363, 2002.

Chan. J.K., et al. Effects of dietary alpha-linolenic acid and its ratio to linoleic acid on platelet and plasma fatty acids and thrombogenesis. Lipids. 28: 811-817, 1993.

Emken, E.A., et al . Dietary linolenic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim. Biophys. Acta. 1213: 277-288, 1994.

Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). A report of the Panel on Macronutrients, Subcommittess on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. National Academy Press, Washington , DC , 2002.

Francois, C.A., et al . Supplementing lactating women with flaxseed oil does not increase docosahexaenoic acid in their milk. AJCN. 77: 226-233, 2003.

Gerster, H. Can adults adequately convert a-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int. J. Vit. Nutr. Res. 68: 159-173, 1998.

Hussein, N., et al. Long-chain conversion of [13C]linoleic acid and a-linolenic acid in response to marked changes in their dietary intake in men. J. Lipid. Res. 46: 269-280, 2005.

Lamptey, M.S., and Walker, B. L. A possible essential role for dietary linolenic acid in the development of the young rat. J. Nutr. 106(1): 86-93, 1976.

Pawlosky, R. J., et al . Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J. Lipid Res. 42(8):1257-1265, 2001.

Cheers biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Research Lovers,
A new research study would seem to indicate that we need to keep our intestinal bacteria levels high ( good bacteria) if we are to develop a good immune system and avoid things like colitis. This research also appears to support the to much hygiene theory.
http://www.newscientist.com/channel/health...protect-us.html?

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Hearing loss is exacerbated by smoking and obesity according to a study just released in New Scientist. For a long time researchers have known that noise exposure destroys the sound-transducing hair cells in the inner ear, but now in a large study ( 4000 people in 9 European countries) have found that by staying slim, drinking one alcoholic drink per week and not smoking you can save 50% of your hearing loss. In other words these lifestyle things cause 50% of hearing loss because they reduce circulation to the inner ear.

http://www.newscientist.com/channel/health...afness.html?fee

Cheers Isn't science great? ..biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
This is another positive study on the value of drinking coffee, this was a large study and it also mentions the defective gene that was discovered about 3 years ago (2005). Michael T. Murray wrote about this gene in his newsletter back then, apparently 86% of the Asian population possess a gene that would instill a positive heart disease outcome for them from drinking coffee, whereas westerners were thought to be 50/50.

http://www.newscientist.com/channel/health...se.html?feedId=

Cheers biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Tomatoes can now be "flogged" as a beauty therapy, we need some salesmen/women. The British have found Lycopene protects the skin against aging and sun-mediated damage from within. If you have been following the Lycopene research over the past 5 years or so you will easily understand how this can occur. biggrin.gif

Tomatoes found to fight sun damage
News from Newcastle

Tomatoes could be the new weapon in the fight against sun damage to the skin, research at the Universities of Newcastle and Manchester has revealed.

According to a study presented at the British Society for Investigative Dermatology this month, eating tomato paste could help protect against sunburn and sun-induced skin ageing.

In the study, researchers compared the skin of 20 people, half of whom were given five tablespoons (55g) of standard tomato paste with 10g of olive oil every day, with the other half receiving just olive oil, over a period of 12 weeks.

The skin was exposed to ultraviolet (UV) light - which is found naturally in sunlight - at the beginning and end of the trial. The team found significant improvements in the skin’s ability to protect itself against UV in the group who had been eating tomato paste.

Professor Lesley Rhodes, dermatologist at the University of Manchester, says, “The tomato diet boosted the level of procollagen in the skin significantly. These increasing levels suggest potential reversal of the skin ageing process. This is in addition to the significant reduction in sunburn.

“These weren’t huge amounts of tomato we were feeding the group. It was the sort of quantity you would easily manage if you eating a lot of tomato-based meals.

“People should not think that tomatoes in any way can replace sun creams, but they may be a good additive. If you can improve your protection through your diet then over several years, this may have a significant effect.”

Many of the harmful effects of UV light are due to the excess production of harmful molecules known as ‘reactive oxygen species’ which can damage important skin structures. Sun damage from UV exposure includes premature wrinkles and skin cancer.

The tomato’s key skin saving property is a powerful antioxidant called ‘lycopene’, which is able to neutralise or ‘quench’ the harmful molecules.

Lycopene is the bright red pigment found in a number of red fruit and vegetables, but with its highest levels in cooked tomatoes. As tomato paste contains a high concentration of cooked tomatoes, it is an ideal source of lycopene.

Compared to the control group, the group who had eaten the paste were found to have 33 per cent more protection against sunburn, which can lead to skin cancer. The researchers calculated the protection offered by the tomato paste to be equivalent to a sunscreen with a sun protection factor (SPF) of 1.3.

By looking at the effects on skin ageing by studying skin samples taken from both groups, before and after trial, the Manchester team discovered that the tomato diet had boosted the skin’s levels of procollagen, a molecule which gives the skin its structure and loss of which leads to skin ageing and lack of elasticity.

Meanwhile, collaborators at Newcastle University found that the lycopene had reduced damage to mitochondrial DNA in the skin, which is also believed to be linked with skin ageing.

Professor Mark Birch-Machin, dermatology scientist from Newcastle University, says, “Eating tomatoes will not make you invincible in the sun, but it may be a useful addition to sun protection along with sunscreens, shade and clothing.

“The protective effect of eating tomatoes on our mitochondria is important as they are the energy producers in all our body cells including skin. Therefore being kind to our mitochondria is likely to contribute to improved skin health, which in turn may have an anti-ageing effect.”

Nina Goad of the British Association of Dermatologists says “While the protection offered by lycopene is low, this research suggests that a diet containing high levels of antioxidant rich tomatoes could provide an extra tool in sun protection.”

The team is now looking to start a new, longer-term study into the protective effects of lycopene on the skin.

Presentation: “Lycopene protects against biomarkers of photodamage in human skin”; M. Rizwan, I Rodriguez-Blanco, A. Harbottle*, M. Birch-Machin*, R.E.B. Watson and L.E. Rhodes; Dermatological Sciences, University of Manchester and *Dermatological Sciences, Newcastle University.

Published in collaboration with the British Association of Dermatologists.

Staff profile: Prof Mark Birch-Machin

published on: 29th April 2008



It is very difficult to improve on nature so this is the form I would be taking my Lycopene. biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Did you know that flaxseed slows the growth of prostate tumours and ginseng alleviates the fatigue of cancer patients.



ABC News

Video Audio Photos | Podcasts/RSS Email

News Home Just In Australia World Business Sport Entertainment Weather | Opinion Blogs
Preferences

Hot tags: australia, government-and-politics, law-crime-and-justice, business-economics-and-finance, states-and-territories, community-and-society, world-politics, united-states, qld, sport

Print Email Add to My Stories
Flaxseed, ginseng hold up in cancer trials

Posted Sun Jun 3, 2007 12:51pm AEST

US research into alternative medicines suggests flaxseed slows the growth of prostate tumours and ginseng helps relieve the fatigue of cancer patients.

The studies reflect doctors' efforts to explore the risks and benefits of foods and supplements that are routinely taken by their patients with little scientific proof they help.

Americans spend between $US36 billion and $US47 billion a year on complementary and alternative therapies, according to the National Centre for Health Statistics.

"Patients are taking these compounds but we need to know if they are doing any good or any harm," said Dr Bruce Cheson of Georgetown University Hospital in Washington, who led a panel on alternative therapies at a meeting of the American Society of Clinical Oncology.

In the flaxseed study, researchers at Duke University Medical Center in North Carolina and colleagues evaluated the seed's role as a food supplement in 161 men who were scheduled to undergo surgery for prostate cancer.

"The growth rate was decreased in the men who got flaxseed," said Dr Nancy Davidson, an oncologist at Johns Hopkins University in Baltimore who is president-elect of ASCO.

"I think this is fascinating."

Flaxseed is rich in omega-3 fatty acids and lignans, a fibre found on the seed coat.

"We were looking at flaxseed because of its unique nutrient profile," said Wendy Demark-Wahnefried, a researcher in Duke's School of Nursing, who led the study.

Half of the men in the study added 30 grams of flaxseed daily to their diets for about 30 days. Half of the flaxseed group also went on a low-fat diet.

After the surgery, the researchers looked at the men's tumour cells to see how quickly the cancer had multiplied.

The cancer cells in both the flaxseed groups grew about 30 to 40 per cent slower than the control group.

But Dr Demark-Wahnefried is not ready to prescribe flaxseed.

"It's a healthy food. It has a lot of vitamins and a lot of fibre. But we cannot definitively say at this point you should take flaxseed because it is protective against prostate cancer," she said, adding that flaxseed now needed to be studied to see if it can prevent prostate cancer.

Ginseng

In the ginseng trial, Debra Barton of the Mayo Clinic in Rochester, Minnesota, and colleagues tested three different doses of the herb on patients with a variety of cancers who were expected to live at least six months.

Twenty-five percent of patients taking a 1,000mg dose and 27 per cent of patients taking a 2,000mg dose said their fatigue symptoms were "moderately better" or "much better."

Only 10 per cent of those taking a 750mg dose reported an improvement, which was about the same as the placebo group.

Patients in the trial took Wisconsin ginseng from a single crop that was tested for uniform potency. It was powdered and given in a capsule form.

"I wouldn't have predicted this, I have to admit," Dr Davidson said in an interview. "We might want to test this on a large scale."

The flaxseed study was funded by the National Institutes of Health and the ginseng study was supported by US Public Health Service grant

Cheers biggrin.gif unsure.gif biggrin.gif
John Bobbin BNat
Hi Science Readers,

In the July/August 2008 edition of the peer reviewed "Journal of Complementary Medicine" Journal Digest section there is a nice piece of research on menopause symptoms and soya isoflavones.

Several double blinded, placebo controlled trials have been conducted in the past that have yielded mixed results, creating confusion amongst practitioners and patients alike, now an explanation is at hand.

It has been theorised in the past that the conversion of diadzein to equol may hold the key, so this research was set up to investigate that. Diadzein is contained in abundance in soy beans but it require bacteria in the intestine to convert it to equol. (http://www.medterms.com/script/main/art.asp?articlekey=32272).

Urine samples were taken from the ladies after one week on soya germ extract, and then they were divided into two groups based on the presence of equol in the urine. Those ladies that did not convert diadzein to equol did not get anywhere near as much reduction in hot flushes or excessive sweating as those that could make the conversion. 66 women were in the intention to treat group and from this (n=34) could convert- (n=32) could not convert. Placebo (n=30).

From this you can see it is almost 50% of women can/cannot convert diadzein to equol.

This original research can be found in Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/18395723?dopt=Abstract

Cheers biggrin.gif biggrin.gif
John Bobbin BNat
Hi Science Readers,
Here's an interesting bit of investigative work, by hybridising human and frog's brains researchers move a step closer to understanding Autism.

Health

Human-frog hybrids aid autism investigations

* 22:00 21 July 2008
* NewScientist.com news service
* Ewen Callaway

Printable versionEmail to a friendRSS FeedSyndicate


* MOST VIEWED
* MOST COMMENTED

Most popular yesterday

Chemical breakthrough turns sawdust into biofuel

Invisible nanotube cable could support a human

Babies use grown-up memory tricks


Dangerous faults reveal themselves in the landscape

Most commented yesterday

Chemical breakthrough turns sawdust into biofuel

Invisible nanotube cable could support a human

Cleaner skies explain surprise rate of warming

Bacteria make major evolutionary shift in the lab

The Big Questions: What happens after you die?
MOST POPULAR
Tightrope act
High-tech high wire
A theoretical cable made of nanotubes could be invisible but still support a human




Human-frog hybrids might reveal the neurological secrets of autism. By fusing cells from the preserved brains of deceased autistic patients with the eggs of a carnivorous African frog called Xenopus, scientists have started investigating the way the brain cells of people with autism behave.

The frog eggs work a little like human neurons and the hybrid cells act as a surrogate of a living brain with the condition.

"It's almost as if you were studying a neuron in the human brain," says Ricardo Miledi, a neurobiologist at the University of California, Irvine, who developed the approach and has previously used Xenopus eggs to study epilepsy.

Miledi's earlier work has suggested that some brain cells of epilepsy patients have trouble sensing a molecule that helps damp down neuron activity. The proteins in question, called neurotransmitter receptors, sense the chemicals that neurons use to communicate, and Miledi thinks that proble

Some researchers blame autism on a malfunction in mirror neurons, cells that play a vital role in understanding the actions of others people.ms with these proteins underlie epilepsy and other disorders.

To see if abnormalities in neurotransmitter signalling also underlie autism, Miledi's team collected brain samples from six deceased autistic patients, aged eight to 39. They fused brain-cell membranes, which house neurotransmitter receptors, together with Xenopus egg membranes. As a control, they did the same thing with brain cells from patients with no history of mental disorder.

Miledi's team then doused the frog eggs in neurotransmitter chemicals, and measured the voltage generated within each egg. The neurotransmitter chemicals tell brain cells to pump charged molecules in and out the membrane, creating a voltage across the membrane. Since Xenopus eggs do not respond to the neurotransmitters, the human proteins are completely responsible for any electric current generated.

Four of six autistic brains responded to neurotransmitters chemicals less vigorously than the controls.

However, Miledi cautions that more research with additional samples will be needed to firm up any conclusions. "Autism spectrum disorder is a very broad range of maladies, with many different sources and many different problems," he says.

Jonathan Pevsner, a neurobiologist at Kennedy-Krieger Institute in Baltimore, Maryland, agrees that frog eggs could be useful for studying certain properties of autism, and perhaps uncovering new treatments.

He notes that other mental illnesses, such as depression and Parkinson's, can be treated by turning the activity of neurotransmitters up or down. Hybrid frog eggs could perhaps hint at which neurotransmitters to tweak, he says.

Journal reference: PNAS (DOI: 10.1073/pnas.0804386105)

Cheers unsure.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Confusion, inability to concentrate and sleep loss maybe caused by a partially blocked bladder this may explain the symptoms often seen in aging.

http://www.newscientist.com/channel/health...th-the-mind.htm

Cheers unsure.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Science Readers,
Remember Linus Pauling (Winner of 2 Nobel Prizes) he always claimed Vitamin C could beat cancer when used in massive doses, I have his book in my library.

Health

Vitamin C jabs may combat cancer

* 22:00 04 August 2008
* NewScientist.com news service
* Peter Aldhous

Printable versionEmail to a friendRSS FeedSyndicate


* MOST VIEWED
* MOST COMMENTED

Most popular yesterday

World's smallest snake discovered

'Gravity tractor' could deflect asteroids

Mangled stars could reveal ejected black holes

Arctic ice continues to thin

Back to basics for failed HIV vaccine
smart

Most commented yesterday

Arctic ice continues to thin

Cosmic rays may prevent long-haul space travel

Biofuels emissions may be 'worse than petrol'

Five ways to trigger a natural disaster

Electrode lights the way to artificial photosynthesis
SPACE BLOG
Mars soil
Phoenix news
News about the 'potential for life' on Mars might be bad

SHORT SHARP SCIENCE BLOG
Anthrax killer?
Debora MacKenzie met the US researcher prior to his suicide - was he behind the attacks of 2001?

VIDEO NEWS
Video roundup with Sean O'Neill
Best of the week
Movie Camera
Sean O'Neill presents: sexually deceptive male fish, bees that are like serial killers, and more...

PICTURE OF THE DAY
Earth crust rock geology
Naked Earth
This image shows the different types of rock found in the top layer of crust

TECHNOLOGY NEWS
Bullet
Bullet IDs
Covering bullet cartridges with pollen could link suspects to gun crimes


Could injections of vitamin C help treat cancer? That's the suggestion from a new study in mice – and trials are already under way to test similar injections in people.

But some cancer specialists are sceptical, and fear that desperate patients will be prompted to start taking large doses of the vitamin. That may be dangerous, because antioxidants such as vitamin C could undermine the effectiveness of standard cancer drugs and radiation therapy.

Excitement over the idea of treating cancer with vitamin C grew in the 1970s after the Nobel prize-winning chemist Linus Pauling suggested that it helped terminally ill patients survive for longer.

However, in 1985, two placebo-controlled trials found no effect of taking vitamin C pills.

In the current study, researchers led by Mark Levine of the National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, Maryland, gave vitamin C to mice intravenously.
Oxidation boost

The researchers injected immune-deficient mice with cells from three aggressive human cancers – ovarian and pancreatic tumours, plus a form of brain cancer called glioblastoma – and found that vitamin C injections slowed tumour growth by up to 53%.

By injecting into the bloodstream, Levine explains, it is possible to get much larger amounts of the vitamin to a tumour than is possible with oral supplements. While vitamin C is usually an antioxidant, under these circumstances it causes the formation of hydrogen peroxide, a powerful oxidising agent that kills cancer cells.

Levine suggests that intravenous vitamin C could be a useful addition to conventional cancer therapy. His team has also found that women in a preliminary clinical trial are getting similar doses of vitamin C to those seen in the experimental mice. "It's pharmacologically achievable," Levine says.

That trial, led by Jeanne Drisko of the University of Kansas in Kansas City, aims to recruit 50 women to test the safety of giving intravenous vitamin C, plus other antioxidants given orally, on top of existing therapies for ovarian, cervical or uterine cancer.

Although there is little evidence that it works in humans, Drisko's clinic also offers intravenous vitamin C to paying patients.
Self-medication risks

Meanwhile, the Cancer Treatment Centers of America (CTCA) in Zion, Illinois, is testing the safety of intravenous vitamin C in late-stage cancer patients for whom there is no other treatment option. So far, 10 out of a planned 18 patients have been enrolled into the trial.

Definitive answers on the effectiveness of intravenous vitamin C will only come from subsequent larger trials. But given recent experiences with a drug called DCA, which some patients began taking without medical supervision after reading about promising results on cancer cells, there are concerns that patients may take matters into their own hands by injecting themselves with vitamin C or taking large doses of vitamin C pills.

Many cancer patients take antioxidant vitamins, often without telling their doctors. While Drisko and other backers of complementary approaches suggest that antioxidants can aid therapy and reduce side-effects, conventional chemotherapy and radiotherapy are thought to work in part by generating free radicals which kill cancer cells.

Because antioxidant vitamins can mop up these radicals, they may interfere with cancer therapy, other researchers warn. "You want to make sure you're not taking supplemental vitamins," says David Agus, an oncologist at the Cedars-Sinai Medical Center in Los Angeles.

Journal reference: Proceedings of the National Academy of Sciences (DOI: 10.1073/pnas.0804226105

Cheers unsure.gif biggrin.gif unsure.gif biggrin.gif
John Bobbin BNat
Hi Readers,
You don't need gyms, you don't need supplements, all you need is joggers!

Main Page
Previous: Healthy gaming
Can we slow down the aging clock?
by Dr. Marla Shapiro on Tue 12 Aug 2008 07:00 AM EDT | Permanent Link

With the silver tsunami rapidly approaching, the question remains can we slow down the aging clock? A study this week out of the Archives of Internal Medicine looks at running and finds that indeed it can slow the human aging clock. There has been concern that running and high impact sports would contribute to osteoarthritis and increasing disability. In fact, several studies have shown exactly the opposite.


Osteoarthritis is a form of arthritis where there is degeneration of the joint. It often has been called wear-and-tear arthritis. In an earlier study by the same authors out of Stanford University, it was found that painless running or any other aerobic activity will keep you fit and arthritis free. It is only when there is a tearing or an injury that damages the structure of the joint that arthritis can be accelerated .

Earlier studies showed that those who get the most benefit from running are those who run between 6 and 20 miles a week. Their earlier studies by the same Stanford group, showed that 20% of those who did not exercise had pain and disability as compared to 5% of the regular runners. Exercises that might accelerate tearing around the joints such as football and soccer are more likely culprits in accelerating osteoarthritis.

James Fries, one of the authors of the present paper questioned whether running and regular exercise would not only extend longevity, but also would compress the period of the end of life where people could not carry out their regular tasks. This he called 'the compression of morbidity theory'.

In the present study, some 538 runners over the age of 50 were compared to a similar group of non-runners. The runners at the beginning of a study were found to be younger, leaner and less likely to smoke compared to the controls. They ran an average of about 4 hours per week but after 21 years, their running time had decreased to an average e of 76 minutes per week. Despite the decrease in running, the runners were still seeing health benefits compared to non runners.

Both groups were questioned about disability. The areas of disability examined were independent running, dressing, grooming, hygiene, eating, walking, reaching, ability to grip and routine physical activity. All of these are essential qualities for independent living. Not only did running delay disability, but the gap between runners’ and non-runners’ abilities got bigger with time. In fact, runners’ disability was delayed by 16 years compared to the non-runners. In addition there was reduced dementia in those who exercise.

The difference in disability continued to be seen well into the 9th decade. This effect can largely be explained by greater lean body mass and healthier habits in general

After 19 years, 15% of runners had died compared to 34% of the controls. Not only were there lower rates of death from cardiovascular diseases such as heart attack and stroke, but there was a greater reduction of cancers seen in runners including lung, colon, breast and hematological cancers. There were also fewer deaths due to neurological disorders and infections including pneumonia.

Explanations for improvement in both disability rates as well as mortality includes the effect of exercise on increased cardiovascular fitness, improved aerobic capacity, better organ reserve, increases in skeletal mass, improved metabolic functioning of muscles that leads to decreased frailty, lower levels of circulating inflammatory markers, an improved response to vaccinations and improvement in higher cognitive functions such as thinking, learning and memory functions.

What is most impressive about this study is that between runners and non-runners there was a sustained improvement as far out as 21 years.

With age- adjusted death rates reaching record lows and life expectancy reaching record highs, it is important that we not just live longer but live well and live independently. It is clear that regular running and vigorous exercise is associated with reduced disability in lower life, and as the authors point, out a notable survival advantage. Running indeed not only slows down the aging clock but might allow you to literally outrun the aging clock

It has taken a long time but finally jogging is vindicated!!
Cheers biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Everyone,
Recently investigators have found a role for serotonergic antidepressant medications in the treatment of premenstrual syndrome (PMS). Using several research institutions in Iran a clinical trial was conducted to research the efficacy of saffron, a herb with antidepressant activity that seems to indicate serotonergic action, in the treatment of PMS. n=54 recruited from the departments of Gynaecology and Obstetrics at Tehran and Zanjan Universities for this 4 month trial. Conclusion showed saffron to be an effective, well tolerated treatment for PMS. (Agha-Hosseini M, et al. Crocus sativus L. (Saffron) in the treatment of premenstrual syndrome. British Journal of Obstetrics and Gynaecology 2008)
Cheers biggrin.gif biggrin.gif
John Bobbin BNat
Hi Devoted Followers of Science,
The efficacy of zinc as a treatment for colds has yielded mixed results over a large number of trials and years.
Investigators have suggested that the type of zinc as well as its dosage may be the reason for the mixed results. A new study from Wayne State University School of Medicine (Detroit, Michigan,US) and University of Michigan Medical School (Ann Arbor, Michigan) performed a randomised, double blind, placebo controlled trial to evaluate the efficacy of zinc acetate lozenges in the treatment of the common cold. n=50, mean age 35.2 years were included in the trial over 4 years.
Conclusion - Administering zinc acetate lozenges within 24 hours of the onset of the common cold reduced the common cold symptoms duration and severity, possibly through a combination of anti-oxidant and anti-inflammatory actions. (Prasad AS, Beck FWJ,Bao B, et al. Duration and severity of symptoms and levels of interleukin -1 receptor antagonist, soluble tumour necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. Journal of Infectious Diseases 2008)

We badly need good quality trials testing the efficacy of zinc acetate vs zinc gluconate vs zinc amino acid chelate vs zinc citrate. Results of this would inform clinicians as to the best form of zinc lozenge to use for their patients.

Cheers unsure.gif unsure.gif biggrin.gif biggrin.gif
John Bobbin BNat
Welcome back readers of truth,
Acute bronchitis is one of the most common diagnosis in primary care. Typically caused by viral infection conventional medicine has little to offer patients suffering from this condition. Using the major medical databases Medline, AMED, CINAHL, Embase and the Cochrane Library, researchers from the Univesities of Exeter and Plymouth conducted a systematic review and meta-analysis to determine the efficacy of Pelargonium sidoides( A South African herb) in treating this condition. Only high quality randomised controlled trials that examined mono preparations were included in the trial, six met the entry criteria ( 4 published and 2 unpublished ). $ trials involved adults and 2 involved children aged 6 to 18. n=1012.
The authors concluded that P.sidoides is significantly more effective than placebo in the treatment of acute bronchitis. (Agbabiaka TB, et al. Pelargonium sidoides for acute bronchitis. Phytomedicine 2008)

Cheers biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
Here is a warning, do not use anything with colloidal silver in it.
rug Reactions Bulletin > October 2007
Safety information

* Alerts/advisories
* Product recalls
* Report a problem
* Safety monitoring

Australian Adverse Drug Reactions Bulletin

Volume 26, Number 5, October 2007

Prepared by the Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA.
Contents

* Thiazolidinediones and reduced bone density
* Renal impairment with zoledronic acid
* Dangers associated with chronic ingestion of colloidal silver
* Drugs of current interest
* What to report

How to access a pdf document

Printable version of this bulletin (pdf,42kb)
Thiazolidinediones and reduced bone density

Thiazolidinediones include rosiglitazone (Avandia and Avandamet) and pioglitazone (Actos). These medicines act to increase insulin sensitivity and are widely prescribed to treat type II diabetes mellitus. Recent evidence suggests thiazolidinediones are associated with an increased risk of peripheral fractures in post-menopausal women.

The ADOPT study1 was a randomised, double-blind, parallel group study that followed the progression of 4360 recently diagnosed patients with diabetes mellitus for a median of 4.0 years. The incidence of fractures in women taking rosiglitazone was 9.3% (2.7 patients per 100 patient years), compared with 5.1% (1.5 patients per 100 patient years) in those taking metformin and 3.5% (1.3 per 100 patient years) in those taking glibenclamide. The majority of fractures in these patients were in the humerus, hand, or foot. The incidence of fractures of the hip or spine in women and the incidence of fractures in males were similar among the 3 treatment groups.

A sponsor-initiated review of fracture risk in pioglitazone-treated patients treated for up to 3.5 years also found more fractures in female patients taking pioglitazone than those taking a comparator. There was no increased risk of fracture identified in men.

The sponsors of rosigltazone2 and pioglitazone3 have updated product information documents for these medicines and issued letters to healthcare professionals describing the above findings.

The mechanism for increased fracture risk was examined in a 14 week study in 50 healthy postmenopausal women in New Zealand.4 This study showed reductions in markers of bone formation in women taking rosiglitazone 8 mg/day compared with placebo. These changes were evident after 4 weeks and persisted for the duration of the study. There were also small reductions in hip and lumbar spine bone density in women taking rosiglitazone.

The full clinical significance of these recent findings is yet to be determined. However, the risk of fracture should be considered for all patients, especially women, taking or being considered for treatment with thiazolidinediones. For these patients, as for all patients with type 2 diabetes mellitus, attention should be given to assessing and maintaining bone health according to current standards of care.
Reference

1. Kahn S et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEJM 2006; 355: 2427-43.
2. GlaxoSmithKline Australia Pty Ltd: Avandia, Avandamet
3. Eli Lilly Australia: Actos
4. Grey A et al. The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrin Metab. 2007; 92:1305-1310.

Top of page
Renal impairment with zoledronic acid

There is a well-known risk of deterioration in renal function with intravenous bisphosphonates administered at a rapid infusion rate. ADRAC has received few reports of renal impairment or failure with pamidronate and the oral bisphosphonates risedronate and alendronate, but there is a significant number with zoledronic acid (31 from a total of 268 reports for this drug). While the deterioration in renal function with zoledronic acid (Zometa) was usually acute, in many cases it did not appear to be related to a rapid infusion rate.

The 31 reports in association with zoledronic acid describe either renal failure (16) or renal impairment (15). It was the only suspected drug in 20 of the 31 reports. Interstitial nephritis was described in 3 of the reports. Ages ranged from 44 to 88 years (median 63 years). Time to onset in about two thirds of the reports was between 1 and 3 months after starting zoledronic acid. Recovery was mostly unknown or unspecified.

Zoledronic acid was being used for a variety of indications with multiple myeloma (13 cases) the most common but also breast cancer (5), prostate cancer (4), plasmacytoma, malignant melanoma, osteoporosis, bone metastases and osteomyelitis (1 case each). Only 4 reports did not specify the reason for use.

The Zometa product information1, under Precautions, includes comprehensive information on the need to monitor renal function and use in patients with pre-existing renal impairment. It also provides detailed information on risk factors for renal adverse events which include dehydration, pre-existing renal impairment, multiple cycles of bisphosphonates, as well as the use of other nephrotoxic drugs, or using an infusion time shorter than 15 minutes. Renal impairment and renal failure are both mentioned under Adverse Reactions as common (1-10%) and uncommon (0.1-1%) respectively.

Reports to ADRAC suggest renal impairment and renal failure may occur more commonly with zoledronic acid than with other bisphosphonates.

In several cases, the delayed onset of renal toxicity suggests the impairment was unrelated to the infusion rate; although the conditions in which zoledronic acid is used may predispose patients to renal impairment. Many of the reports described patients with pre-existing renal impairment, and the use of zoledronic acid in multiple myeloma is also a confounding factor.

ADRAC reminds prescribers of bisphosphonates to pay close attention to risk factors for renal impairment and to adhere strictly to the instructions for use.
Reference

1. Zometa product information. Novartis Pharmaceuticals Australia Pty Ltd (version dated February 2006)

Top of page
Dangers associated with chronic ingestion of colloidal silver

ADRAC has received four reports of silver toxicity (argyria) following ingestion of homemade products containing colloidal silver (tiny particles of metallic silver suspended in liquid) prepared using a "colloidal silver generator":

* A 5 year old boy who ingested colloidal silver daily for several months developed grey discolouration of skin and tongue and abnormal hepatic function.
* An elderly man who drank colloidal silver daily for 6 months required hospital admission for debilitating fatigue accompanied by blue skin discolouration, dilated cardiomyopathy, amnesia and incoherent speech.
* An elderly man consuming liquid made using a "colloidal silver generator" over a 4 year period developed grey skin discolouration.
* An adult male ingesting homemade colloidal silver daily for 3 years and also applying it topically after shaving developed generalised skin discolouration.

In each case, the plasma silver concentration was many times higher than in subjects not knowingly exposed to silver (background levels up to 2.3 µg/L have been reported1).

There are no products containing colloidal silver approved for marketing in Australia.2 With the exception of registered topical silver preparations, there is no evidence to support the safety or efficacy of silver regardless of its form or method of manufacture.3 In addition, silver has no known nutritional benefit and its well-defined toxicity can occur with all forms of the metal, including silver salts and colloids3,4 Despite this, claims of therapeutic benefit continue to be made for colloidal silver products.

While the TGA will take action to stop the supply of unapproved colloidal silver products that make therapeutic claims, "colloidal silver generators" are currently exempt from regulation and therefore remain available in Australia.

Argyria is the main toxicity associated with chronic ingestion or topical absorption of silver, including colloidal forms of silver. It is characterised by an irreversible, generalised blue-grey discoloration of the subepithelial layer of skin. Later, the entire skin, deep tissues, mucous membranes, nails, conjunctiva, cornea, and lens may be affected.

Argyria discolouration may be misdiagnosed as cyanosis, methaemoglobinaemia or haemochromatosis. Other toxicities associated with ingested silver may include peripheral neuropathies, seizures, and haematological, cardiac, hepatic and nephrotoxic derangements.3,4

ADRAC has received no reports of argyria associated with legitimate therapeutic goods containing presentations of silver that remain appropriate, for example, topical silver nitrate for neonatal conjunctivitis or silver sulfadiazine for burns.

Patients seeking information on claimed benefits of colloidal silver should be advised of the lack of evidence for therapeutic benefit and the potential for toxicity associated with colloidal silver preparations. Patients should be strongly discouraged from using products made with "colloidal silver generators".
Reference

1. Wan A T et al. Determination of silver in blood urine and tissues of volunteers and burn patients. Clin. Chem. (1991); 37:1683
2. http://www.tga.gov.au/docs/html/csilver.htm
3. Federal Register: August 17, 1999 (Volume 64, Number 158) [Rules and Regulations] Over-the-Counter Drug Products Containing Colloidal Silver Ingredients or Silver Salts
4. White J et al. Severe generalized argyria secondary to ingestion of colloidal silver protein. Clinical and Experimental Dermatology 2003; 28: 254-25

Cheers unsure.gif unsure.gif
John Bobbin BNat
Hi Science Lovers,
They have just found a way to track and watch virus's as the do their devious work on the human body.

Virologists have a new weapon in the war against viruses – a way to tag and track individual viruses that are too small to be viewed with light microscopes.

To infect a cell, viruses have to subvert the cell's proteins in order to survive and replicate inside. But working out exactly what a virus is doing is difficult because they are so small. Most are 10-300 nanometres across.

Pin Wang and colleagues at the University of Southern California have come up with a way to track individual viruses. "That is a powerful tool for investigating viral infection routes," he told New Scientist.

Until now only one group of viruses – the lentiviruses, which include HIV – could be tracked as they moved through a cell. In 2002, Thomas Hope and colleagues at the University of Illinois tagged HIV-1 with a fluorescent protein called GFP, revealing that it travels through cells by hitching a ride on the protein struts that make up their "skeleton".
Track and trace

Wang's team says that a kind of nanoscale crystal called quantum dots can track a larger variety of viruses.

Just a few nanometres in diameter, their small size makes them subject to quantum effects that make them shine very brightly for hours after being hit with laser light. Together, those properties are perfect for tagging tiny viruses.

Wang's team labelled HIV-1 viruses by attaching them to molecules of biotin (vitamin B7), which in turn connects to a protein coated onto the quantum dots.

To check this method didn't affect the quantum dots' shine or the way viruses behave, the team simultaneously tracked HIV-1 particles using quantum dots, and GFP.

They found that the viruses labelled with quantum dots infected cells as readily as unlabelled viruses.
None shall escape

Wang says that quantum dots could be used to track a much wider range of viruses, including those that can't be followed using GFP.

"We believe that many kinds of enveloped viruses could be labelled by our method," he says.

Although some viruses can be labelled using dye molecules, they are quickly bleached by the powerful light of microscopes. By contrast, quantum dots retain their brightness for several hours.

"Some studies show that quantum dot-labelled proteins could be detected in living cells even after 48 hours," Wang adds.

Maxime Dahan at the Ecole Normale Supérieure in Paris is impressed with the study.

"It unquestionably represents a significant result in terms of using quantum dots as virus markers," he says. "It holds great promise to unravel the infection pathway in a detailed manner."

Journal reference: ACS Nano, DOI: 10.1021/nn8002136

Nanotechnology - Follow the emergence of a new technology in our continuously updated special report.

Quantum World - Learn more about a weird world in our comprehensive

You know you have to have a lot of respect for medical researchers, they never quit regardless of how hard it gets, unless of course the funding dries up. They continually chip away at what must, at times, seem an impossible task.

Cheers biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
I have included this post here as well, it is so important I hope everyone reads it.


American Institute for Cancer Research
Search
Home
Donate Now
Contact Us

Research | Diet & Cancer | Publications | Cancer Survivors | How Can I Help? | Press | About AICR
Press
Press Releases
Health Features
Ever Green
AICR Experts
Press Registration
whitebar.gif
Subscribe to
e.Newsletter
Home


For Immediate Release: April 30, 2008

Contacts: Shannon Campbell 202-328-7744 x235
Glen Weldon 202-328-7744 x312

Cancer Experts Issue Seasonal Warning on Grilling --
With an Important Research Update

Smart Precautions Can Reduce Grilling Risks,
But What You Grill Should be Central Concern
WASHINGTON, DC – This year, as Americans make ready to fire up millions of backyard grills, there’s a new scientific wrinkle: according to an exhaustive analysis of international research on diet and cancer, it’s time to start looking for an alternative to the humble hot dog.

Experts at the American Institute for Cancer Research (AICR) are marking the onset of cookout season by issuing their yearly advice on ways to lower potential cancer risks associated with grilling. But this year, new information has come to light on the precise nature of those risks, and AICR’s advice reflects this development with a shift in emphasis.

According to AICR, what you grill is the most important issue. US consumption of hot dogs and hamburgers soars during cookout season, and a recently published landmark AICR report on diet and cancer prevention concluded that diets high in red meat (beef, pork and lamb) and especially processed meats (such as hot dogs) are now a convincing cause of colorectal cancer.

Based on this report, AICR recommends limiting consumption of red meat to 18 ounces (cooked) per week. But the evidence on diets high in processed meat is even more troubling: according to the AICR report’s analysis of the available evidence, every 3.5 ounces (100 grams) of processed meat eaten per day increases risk for colorectal cancer by 42 percent. Because of this, AICR now advises avoiding hot dogs – along with sausages, bacon, ham, cold cuts and other processed meats.

The AICR expert report, Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, reviewed over 7000 studies on all aspects of diet and cancer risk.
Experts Put Risks in Perspective

Compared to such clear and compelling risks, the risks associated with the grilling process itself should be of secondary concern. It is clear that grilling animal products (both red and white meat) causes potent carcinogens called heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs) to arise within food.

These substances have been shown in laboratory experiments to trigger the cancer process. The AICR report concluded that there is limited but suggestive evidence that these substances factor in human cancer, providing one more reason to limit consumption of red and processed meat, however it is cooked.

“We get asked about the risks of grilling every year about this time, and this year the AICR expert report helps put them in perspective,” said AICR Nutrition Advisor Karen Collins, MS, RD.

“There are risks associated with the grilling process, and it makes sense to take precautions to reduce those risks. But keep an eye on the big picture: the evidence is now overwhelming that red meat – especially processed red meats like hot dogs – is a cause of colorectal cancer. So instead of seeing cookout season as incentive to eat more of these foods, look on it as an opportunity to try new things.”
Explore Other Grilling Options

Grilling vegetables and fruit produces no HCAs or PAHs, and thus poses no potential cancer risks. Diets high in plant foods are associated with reduced risk of several cancers.

What about turkey burgers and hot dogs made from turkey or chicken?

Unlike red and processed meat, neither poultry nor seafood has been linked to cancer. But because turkey hot dogs and similar products haven’t been well studied, scientists can’t yet determine if those foods affect cancer risk. The possibility cannot be dismissed, because if, for example, turkey hot dogs are processed in the same manner as beef hot dogs, and some aspect of processing (such as the addition of nitrates) is found to be responsible for increased risk, then turkey hot dogs may confer similar risk. More research is needed.

Note that grilling any form of poultry or fish does produce HCAs and PAHs, so people may choose to take precautions that can minimize the production of these carcinogens.

Smart Precautions Reduce Grilling Risks
If you do choose to cook any kind of meat on the grill this year:

* Select smaller cuts of meat, such as kabobs, and limit your portion size.
* Select leaner cuts, to prevent dripping fat from causing flare-ups, which deposit carcinogens on the meat.
* You can also reduce flare-ups by spreading aluminum foil on the grill. Make small holes in the foil to allow fat to drain.
* Try a marinade. Some laboratory research suggests that even briefly marinating meat significantly reduces the formation of HCAs.
* Partially pre-cook meat briefly in the microwave before grilling, to speed up grilling time.
* Flip meat frequently, which reduces the amount of carcinogens that arise.

The New American (Picnic) Plate

This cookout season, the most important thing to do is to make sure that meat – especially processed meat – isn’t the focus of your meals.

Fill at least 2/3 of your picnic plate with plant foods like salads, beans and grains. Leave a bit of room – 1/3 of your plate or less – for whatever meat you’ve cooked up. That’s a meal model AICR calls the New American Plate, and it’s a pattern of eating that helps you maintain a healthy weight while conferring protection against cancer and other chronic disease.

***

The American Institute for Cancer Research (AICR) is the cancer charity that fosters research on the relationship of nutrition, physical activity and weight management to cancer risk, interprets the scientific literature and educates the public about the results. It has contributed more than $86 million for innovative research conducted at universities, hospitals and research centers across the country. AICR has published two landmark reports that interpret the accumulated research in the field, and is committed to a process of continuous review. AICR also provides a wide range of educational programs to help millions of Americans learn to make dietary changes for lower cancer risk. Its award-winning New American Plate program is presented in brochures, seminars and on its website, www.aicr.org. AICR is a member of the World Cancer Research Fund International

Cheers biggrin.gif biggrin.gif ohmy.gif ohmy.gif
John Bobbin BNat
Hi Science Readers,
A new artificial "muscle" has been developed in Switzland will may save millions of lives, I see it as a fore-runner to something a lot better, read for yourself.



Around 500,000 people in the UK, including Tony Blair, have the heart condition atrial fibrillation, but a new device - the Atripump - could help

An artificial muscle that could offer hope to sufferers of a common heart problem has been developed by scientists.

The implant, called the Atripump, fits on the outside of the heart and applies pressure to keep it beating at the right rate.

It could treat atrial fibrillation, a debilitating heart rhythm disorder.

Around 500,000 Britons suffer from the condition, including Tony Blair.

It occurs when the upper chambers of the heart are out of sync – resulting in a dangerously fast heart beat.

Although not fatal, it can cause fainting, heart failure and blood clots, increasing the risk of stroke.

Common atrial fibrillation treatments include drugs, surgery, electrotherapy or a pacemaker.

Dr Piergiorgio Tozzi, a cardiac surgeon at Vaudois University Hospital in Lausanne, Switzerland, said he developed the Atripump for patients who do not respond well to existing treatments.

The device is made of a domed membrane embedded with wires made from nitinol, a metal alloy used in spectacle frames and internal tubes.

The wires shrink when a small current passes through them, causing the dome to contract, New Scientist magazine reports today.

When the current is off, the wires relax and the dome expands. The two-inch wide device is powered by an internal battery that can be topped up outside the body.

Dr Tozzi said the swelling and contraction of the dome could stop the heart from beating too fast. Although several years from being tested on people, experts believe the Atripump offers hope to patients.

However, the British Heart Foundation has questioned whether the device would be any more effective than a pacemaker

Cheers blink.gif biggrin.gif biggrin.gif
John Bobbin BNat
This could be good research.


Science News
Blocking Key Energy Protein Kills Cancer Cells, First Evidence Provided

ScienceDaily (Apr. 2, 2008) — Researchers in Taiwan report for the first time that blocking a key energy-supplying protein kills cancer cells. The finding, described as the first to test possible medical uses of so-called ATP-synthase inhibitors, may lead to new and more effective anti-cancer medications, according to a new report.
See also:
Health & Medicine

* Breast Cancer
* Cancer
* Lung Cancer
* Brain Tumor
* Prostate Cancer
* Skin Cancer

Reference

* Metastasis
* Isoflavone
* BRCA1
* Tumor suppressor gene

In the new study, Hsueh-Fen Juan and colleagues focused on ATP synthase, a key protein involved in producing the energy-rich molecules of ATP that power all life processes. For years researchers thought that the protein existed only in mitochondria, structures located inside cells that convert nutrients into energy. Recent studies found high levels of ATP synthase on the surface of cancer cells, but until now the medical implications went unexplored.

The researchers analyzed tissue samples from breast cancer patients and found for the first time that the surface of breast cancer cells contains high levels of ATP synthase. In cell studies, exposing breast cancer cells to a substance that blocks ATP synthase killed the cancer cells but did not harm normal cells, the researchers say. The findings suggest that ATP synthase inhibitors may represent a new approach for fighting breast cancer and other cancer types, they say.

Journal reference: "Targeting Therapy for Breast Carcinoma by ATP Synthase Inhibitor Aurovertin B" Journal of Proteome Research. April 4, 2008.
Adapted from materials provided by American Chemical Society, via EurekAlert!, a service of AAAS.
Email or share this story:
Need to cite this story in your essay, paper, or report? Use one of the following formats:
APA

MLA
American Chemical Society (2008, April 2). Blocking Key Energy Protein Kills Cancer Cells, First Evidence Provided. ScienceDaily. Retrieved December 13, 2008, from http://www.sciencedaily.com­ /releases/2008/03/080331092343.htm

In a finding that could lead to more effective anti-cancer medication, scientists exposed breast cancer cells to a substance that blocks a protein called ATP synthase. The cancer cells were killed while normal ones were preserved. (Credit: Courtesy of Hsin-Yi Chang and Hsueh-Fen Juan)

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif

John Bobbin BNat
Hi Readers,
A bit more research which may help fill in the gaps in our knowledge, was forwarded to me today, here it is.



Search the BMJ

BMJ
BMJ Journals
BMJ Careers
BMJ Learning
Evidence Centre
BMJ Group


Search this site:

Advanced search
Register for free services | Subscribe | Sign In
Research
Education
News
Comment
Topics
Print Issues
Home > Research > BMJ 2008;337:a2931, doi: 10.1136/bmj.a2931 (Published 23 December 2008)
Published 23 December 2008, doi:10.1136/bmj.a2931
Cite this as: BMJ 2008;337:a2931

Research
Effect of fish oil on arrhythmias and mortality: systematic review

Hernando León, postgraduate in internal medicine and former postdoctoral clinical research fellow 1,2, Marcelo C Shibata, associate clinical professor1,2, Soori Sivakumaran, associate clinical professor of medicine1,2, Marlene Dorgan, head 3, Trish Chatterley, research librarian3, Ross T Tsuyuki, professor of medicine (cardiology) and director1,2

1 Epidemiology Coordinating and Research (EPICORE) Centre, Edmonton, AB, Canada, 2 Department of Medicine, Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, 220 College Plaza, Edmonton, AB, Canada T6G 2C8, 3 Institute of Health Economics and John W Scott Health Sciences Library, University of Alberta

Correspondence to: R T Tsuyuki ross.tsuyuki@ualberta.ca
Abstract

Objective To synthesise the literature on the effects of fish oil—docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)—on mortality and arrhythmias and to explore dose response and formulation effects.
Design Systematic review and meta-analysis.

Data sources Medline, Embase, the Cochrane Library, PubMed, CINAHL, IPA, Web of Science, Scopus, Pascal, Allied and Complementary Medicine, Academic OneFile, ProQuest Dissertations and Theses, Evidence-Based Complementary Medicine, and LILACS.

Studies reviewed Randomised controlled trials of fish oil as dietary supplements in humans.

Data extraction The primary outcomes of interest were the arrhythmic end points of appropriate implantable cardiac defibrillator intervention and sudden cardiac death. The secondary outcomes were all cause mortality and death from cardiac causes. Subgroup analyses included the effect of formulations of EPA and DHA on death from cardiac causes and effects of fish oil in patients with coronary artery disease or myocardial infarction.

Data synthesis 12 studies totalling 32 779 patients met the inclusion criteria. A neutral effect was reported in three studies (n=1148) for appropriate implantable cardiac defibrillator intervention (odds ratio 0.90, 95% confidence interval 0.55 to 1.46) and in six studies (n=31 111) for sudden cardiac death (0.81, 0.52 to 1.25). 11 studies (n=32 439 and n=32 519) provided data on the effects of fish oil on all cause mortality (0.92, 0.82 to 1.03) and a reduction in deaths from cardiac causes (0.80, 0.69 to 0.92). The dose-response relation for DHA and EPA on reduction in deaths from cardiac causes was not significant.

Conclusions Fish oil supplementation was associated with a significant reduction in deaths from cardiac causes but had no effect on arrhythmias or all cause mortality. Evidence to recommend an optimal formulation of EPA or DHA to reduce these outcomes is insufficient. Fish oils are a heterogeneous product, and the optimal formulations for DHA and EPA remain unclear.


Introduction

An interest in the therapeutic use of n-3 polyunsaturated fatty acids (omega 3 fats, or fish oil) to prevent and treat cardiovascular diseases began after a report in 1976 showed that the high consumption of fish oil in Inuit living in Greenland was associated with a decreased risk of cardiovascular disease.1 The GISSI-Prevenzione trialw1 of 11 324 patients randomised to a mixture of the omega 3 fats eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA, 850-882 mg/day in a ratio of 1.2:1, respectively) or placebo showed a significant reduction in all cause mortality and death from cardiovascular causes over 3.5 years of follow-up. These results seemed to be driven by a reduction in sudden cardiac death, sparking an interest in the potential antiarrhythmic properties of fish oil. Three recent randomised clinical trials looked at fish oil in the prevention of sudden cardiac death in patients with implantable cardiac defibrillators.w2-w4 None of these trials, or a recent systematic review,2 showed a beneficial effect of fish oil on patient outcomes. This may be because of methodological limitations such as overly optimistic estimates of effect sizes, poor patient adherence to the treatment regimen, and high losses to follow-up (all contributing to reduced study power), and the use of different formulations of fish oil (content of EPA and DHA). DHA has been reported to accumulate preferentially over EPA in the plasma membrane of cardiac myocytes.3 4 This might confer a different effect on stabilising the membrane by changing its physical, electrical, and chemical properties. This might also result in DHA having a different influence on cardiac ion channels. In addition, both EPA and DHA are known to inhibit sodium channels, and DHA also inhibits Kv and Kir channels, which are involved in depolarisation and repolarisation of cardiac cells. This might result in different antiarrhythmic properties for each fatty acid.5 6 7 We evaluated the effect of EPA and DHA on all cause mortality and deaths from cardiac causes based on the formulation of these compounds. Previous systematic reviews are inconclusive as they do not include the most recent studies.8 Given the clinical and public health importance of sudden cardiac death, and the lack of clear evidence on the benefit of fish oil in this population, we systematically examined the association between fish oil and arrhythmic events.

Methods

We followed the procedures outlined by the Cochrane Collaboration for systematic reviews.9 In November 2006 two librarians (MD and TC) searched Medline (1966-2006), Embase (1988-2006), the Cochrane Library, PubMed, CINAHL (1982-October 2006), IPA (1970-October 2006), Web of Science, Scopus, Pascal (1987-September 2006), Allied and Complementary Medicine (1985-October 2006), Academic OneFile, ProQuest Dissertations and Theses, Evidence-Based Complementary Medicine, and LILACS using relevant subject headings, Chemical Abstracts Service registry numbers, and a collection of text words representing the concepts of fish oil and cardiac death: "Fish oil", "omega-3 fatty acids", "docosahexaenoic acid", "eicosapentaenoic acid," "docosahexanoic acid", "eicosapentanoic acid", "DHA", "EPA", "unsaturated fatty acid", "N3 fatty acids", "omega fatty acids", "polyunsaturated", "PUFA", "icosapentaenoic acid", "sudden cardiac death", "cardiac sudden death", "ventricular tachycardia", "arrhythmogenic right ventricular dysplasia", "torsades de pointes", "ventricular fibrillation", "heart arrest", "myocardial infarction", "cardiovascular disease", "heart disease", "coronary disease", "heart attack", "heart death", "heart arrhythmia", "heart infarction", "cardiac death", and "coronary artery disease". The terms were not used in every resource—for instance, spellings of words depended on whether American or European databases were being searched. No language restriction was applied. When appropriate we exploded subject headings and truncated terms. The searches in some databases were limited by intrinsic restrictions of those resources—for example, maximum counts for characters. Otherwise, we used strategies as comprehensive as possible. To identify additional papers we reviewed a collection of articles on heart disease and omega 3 fatty acids from the IBIDS database and reference lists of included studies. In March 2007 we updated the search to reduce publication bias as much as possible.
We included studies that tested fish oil as dietary supplements in humans in a randomised controlled trial setting. Trials were excluded if they did not report any of the outcomes of interest, were not randomised, included pregnant women or children, or lasted less than three months.

Outcomes, data collection, and quality assessment
The primary outcomes of interest were the arrhythmic end points of appropriate implantable cardiac defibrillator intervention (confirmed by electrogram) and sudden cardiac death. The secondary outcomes were all cause mortality and death from cardiac causes. Subgroup analyses included the effect of formulations of EPA and DHA on deaths from cardiac causes and effects of fish oil in patients with coronary artery disease or myocardial infarction.

Search results were reviewed to select potentially relevant abstracts. Two investigators, blinded to publication source and authors’ names, independently reviewed the selected abstracts. A third reviewer acted as mediator to resolve any discrepancies. The full text of relevant abstracts was obtained. A data collection form was created and used by two investigators to extract information independently and systematically on the outcomes of interest, inclusion criteria, the risk of bias, and interventions. To ensure accuracy of this procedure the two reviewers compared collected data. A third reviewer acted as mediator for discrepancies.

Two reviewers independently assessed the quality of each study using a form derived from the Jadad criteria.10 In addition, we evaluated other criteria such as concealment of treatment allocation,11 funding agencies, and use of intention to treat analysis.

Statistical analysis
Data were entered into 2x2 tables. We used RevMan 4.2.9 (Cochrane, Copenhagen, Denmark) to analyse results. Data are presented as odds ratios with 95% confidence intervals, using the DerSimonian and Laird random effects model. A value of 0.5 was automatically inserted by the statistical software to allow for reporting of zero events in a category. Agreement between reviewers was measured using kappa analysis and the results were reported using the Cohen kappa index.12 For evaluation of heterogeneity we used both the 2 test and the I2 test. The z test was used to determine overall effect. Assessment of publication bias was carried out by generating a funnel plot from the end points that showed a significant benefit from fish oil.

Dose-response analysis
To evaluate whether a dose-response exists with EPA or DHA we carried out a meta-regression analysis using the random effects model for meta-analysis regression, and analysed the data using STATA software. For this analysis we used the outcome of deaths from cardiac causes, as it was the clinical outcome that was statistically significantly different in the main analyses.

Assessment of safety versus efficacy of fish oil
We evaluated the relative risk of a non-cardiovascular adverse effect occurring in patients who received fish oil compared with placebo. We also expressed treatment effects and adverse effects using the numbers needed to treat to reduce one significant clinical event and numbers needed to harm for an adverse effect.


Results

An initial search retrieved 6713 titles and abstracts, from which 6683 editorials, reviews, letters, non-randomised trials, and studies in animals were excluded. Of the 30 abstracts selected as potentially relevant for review of the full text, nine papers were excluded for not meeting the inclusion criteria, with an agreement by coefficient of 0.92. Therefore 21 papers were considered for data collection and evaluated by two reviewers, with 100% agreement for quality assessment. After excluding three papers with duplicate data13 14 15 and six for not evaluating an outcome of interest,16 17 18 19 20 21 12 studies were included in the final analysis (fig 1).w1-w12

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Believers in Evidence,

Ascorbic acid levels in the diet may be used to control high blood pressure according to this study.



Open AccessHighly AccessResearch
Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young Black and White women

Gladys Block1 email, Christopher D Jensen1 email, Edward P Norkus2 email, Mark Hudes3 email and Patricia B Crawford3 email

1School of Public Health, 50 University Hall, University of California, Berkeley, CA 94720, USA

2Department of Medical Research, Montefiore Medical Center North Division, 600 East 233Street, Bronx, NY 10466, USA

3Nutritional Sciences and Toxicology, 119 Morgan Hall, University of California, Berkeley, CA 94720, USA

author email corresponding author email

Nutrition Journal 2008, 7:35doi:10.1186/1475-2891-7-35

The electronic version of this article is the complete one and can be found online at: http://www.nutritionj.com/content/7/1/35
Received: 23 October 2007
Accepted: 17 December 2008
Published: 17 December 2008

© 2008 Block et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background

The prevalence of hypertension and its contribution to cardiovascular disease risk makes it imperative to identify factors that may help prevent this disorder. Extensive biological and biochemical data suggest that plasma ascorbic acid may be such a factor. In this study we examined the association between plasma ascorbic acid concentration and blood pressure (BP) in young-adult women.
Methods

Participants were 242 Black and White women aged 18–21 yr from the Richmond, CA, cohort of the National Heart, Lung and Blood Institute Growth and Health Study. We examined the associations of plasma ascorbic acid with BP at follow-up year 10, and with change in BP during the previous year.
Results

In cross-sectional analysis, plasma ascorbic acid at year 10 was inversely associated with systolic BP and diastolic BP after adjusting for race, body mass index, education, and dietary intake of fat and sodium. Persons in the highest one-fourth of the plasma ascorbic acid distribution had 4.66 mmHg lower systolic BP (95% CI 1.10 to 8.22 mmHg, p = 0.005) and 6.04 mmHg lower diastolic BP (95% CI 2.70 to 9.38 mmHg, p = 0.0002) than those in the lowest one-fourth of the distribution. In analysis of the change in BP, plasma ascorbic acid was also inversely associated with change in systolic BP and diastolic BP during the previous year. While diastolic blood pressure among persons in the lowest quartile of plasma ascorbic acid increased by 5.97 mmHg (95% CI 3.82 to 8.13 mmHg) from year 9 to year 10, those in the highest quartile of plasma vitamin C increased by only 0.23 mmHg (95% CI -1.90 to +2.36 mmHg) (test for linear trend: p < 0.0001). A similar effect was seen for change in systolic BP, p = 0.005.
Conclusion

Plasma ascorbic acid was found to be inversely associated with BP and change in BP during the prior year. The findings suggest the possibility that vitamin C may influence BP in healthy young adults. Since lower BP in young adulthood may lead to lower BP and decreased incidence of age-associated vascular events in older adults, further investigation of treatment effects of vitamin C on BP regulation in young adults is warranted.

http://www.nutritionj.com/content/7/1/35


Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Science Readers,
This protein looks promising for Alzeimer sufferers.


New Scientist

*
SCIENCE IN SOCIETY

Home |Health | News
Protein reverses Alzheimer's brain damage

* 18:00 08 February 2009 by Andy Coghlan
* For similar stories, visit the Mental Health Topic Guide

Injections of a natural growth factor into the brains of mice, rats and monkeys offers hope of preventing or reversing the earliest impacts of Alzheimer's disease on memory. The benefits arose even in animals whose brains contained the hallmark plaques that clog up the brains of patients.

By delivering brain-derived neurotrophic factor (BDNF) directly into the entorhinal cortex and hippocampus, the parts of the brain where memories are formed then consolidated, the researchers successfully tackled damage exactly where Alzheimer's strikes first.

"We're administering BDNF directly to the degenerating neurons in memory systems of the cortex, and preventing their death," says Mark Tuszynski of the University of California at San Diego. The substance, which naturally supports brain cells throughout life, also amplified the numbers of connections, or synapses, between neurons.

"Our most compelling evidence was the observation that brain cell death was prevented, and that connections between neurons rose in density by about 25%," says Tuszynski. Improvements on this scale happened in all the animals, including mice with a version of human Alzheimer's disease, elderly rats and monkeys with natural degeneration, plus rats and monkeys given brain lesions similar to those seen in Alzheimer's.

To prolong the effects beyond simply injecting BDNF itself, Tuszynski injected a harmless lentivirus carrying the gene for BDNF, so that the chemical would carry on being produced by the virus. He says that pending safety studies, trials could start in two years.

Charles Harrington of TauRx Therapeutics, a company in Aberdeen, UK, developing a drug for Alzheimer's called Rember, questions whether such an invasive treatment would be safe and practical. Also, he says that if the treatment doesn't block the tau protein tangles that accumulate in neurons of Alzheimer's patients, the disease might advance even if cells survive and form connections to others.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Evidence Based Medicine Readers,

Are bad sleeping habits driving us mad?

* 18 February 2009 by Emma Young
* Magazine issue 2696. Subscribe and get 4 free issues.
* For similar stories, visit the Mental Health and The Human Brain Topic Guides

Read our related editorial: Restless or unrested?

TAKE anyone with a psychiatric disorder and the chances are they don't sleep well. The result of their illness, you might think. Now this long-standing assumption is being turned on its head, with the radical suggestion that poor sleep might actually cause some psychiatric illnesses or lead people to behave in ways that doctors mistake for mental problems. The good news is that sleep treatments could help or even cure some of these patients. Shockingly, it also means that many people, including children, could be taking psychoactive drugs that cannot help them and might even be harmful.

No one knows how many people might fall into this category. "That is very frightening," says psychologist Matt Walker from the University of California, Berkeley. "Wouldn't you think that it would be important for us as a society to understand whether 3 per cent, 5 per cent or 50 per cent of people diagnosed with psychiatric problems are simply suffering from sleep abnormalities?"

First, we'd need to know how and to what extent sleep disorders could be responsible for psychiatric problems. In the few years since sleep researchers identified the problem, they have made big strides in doing just that.

Doctors studying psychiatric disorders noticed long ago that erratic sleep was somehow connected. Adults with depression, for instance, are five times as likely as the average person to have difficulty breathing when asleep, while between a quarter and a half of children with attention-deficit hyperactivity disorder (ADHD) suffer from sleep complaints, compared with just 7 per cent of other children.

Until recently, however, the assumption that poor sleep was a symptom rather than a cause of mental illness was so strong that nobody questioned it. "It was just so easy to say about a patient, well, he's depressed or schizophrenic, of course he's not sleeping well - and never to ask whether there could be a causal relationship the other way," says Robert Stickgold, a sleep researcher at Harvard University. Even when studies did seem to point in the other direction, the findings were largely overlooked, he says.
The assumption that poor sleep was a symptom rather than a cause of mental illness was so strong that nobody questioned it

In 1987, for example, Patricia Chang and colleagues at Johns Hopkins University in Baltimore reported a study of 1053 male medical students who had been followed for an average of 34 years after graduation. During that time, 101 of them developed clinical depression and 13 of these committed suicide. It turned out that students who had reported suffering from insomnia were twice as likely to develop depression as those with no trouble sleeping. The team concluded cautiously that insomnia was "indicative of a greater risk" of problems later. Stickgold goes further. He believes the study shows that insomnia can predispose people to depression.

He's not the only one to be persuaded both by findings such as Chang's and by the growing realisation that some sleep problems generate symptoms that mimic those of certain psychiatric disorders.

In 2006, Paul Peppard at the University of Wisconsin-Madison and his team studied the relationship between depression and sleep-disordered breathing. In sleep apnoea, the most common form of SDB, a blockage or narrowing of the windpipe causes a steep drop in oxygen levels, temporarily waking the sleeper. The team randomly selected about 800 men and 600 women from a working population and evaluated them in the lab for SDB and depression. There are four categories of SDB and for each increase in a person's SDB category - from "minimal" to "mild", for example - their odds of getting depressed almost doubled, the team found (Archives of Internal Medicine, vol 16, p 1709). Depression cannot have been the main cause of the poor sleep, since we know SDBs stem from physical factors such as excess fat thickening the windpipe or a large tongue or tonsils relative to the size of the windpipe opening. Instead, this work suggests that sleep disorders lead to the depression.

Indeed, Daniel Buysse, medical director of the Sleep and Chronobiology Program at the University of Pittsburgh, Pennsylvania, has found that treating depressed patients' sleep problems with a drug such as benzodiazepine can produce a dramatic turnaround in their mood disorder. Buysse does not provide an estimate for the proportion of depressed patients who fall into this category - but he has gone on the record saying that for some patients insomnia seems to cause depression.

Poor sleep may also explain some of the characteristic behaviours associated with other mental illnesses. For example, there is plenty of evidence to suggest that impaired sleep can induce the manic episodes suffered by people with bipolar disorder, according to a review published last May (American Journal of Psychiatry, vol 165, p 830). Stickgold even thinks that it can cause a common problem associated with schizophrenia, namely, the failure to master rote tasks such as how to use a piece of machinery. While healthy people improve overnight on tasks that require such motor skills, Stickgold's team has found that people with chronic schizophrenia do not. "We have identified a failure specifically of the sleep-dependent component of procedural learning," the researchers write (Biological Psychiatry, DOI: 10.1016/j.bps.2004.09.012). So, in theory, improved sleep should help with this symptom.
Sleep-deficit disorder

It also seems that behavioural problems resulting from lack of sleep may be misdiagnosed as attention-deficit disorder (ADD) and ADHD. In 2005, Clifford Risk, director of the Marlborough Center for Sleep Disorders in Massachusetts, presented a study to the annual meeting of the American College of Chest Physicians. Of 34 adults with sleep apnoea that he investigated, 16 had scores that suggested a moderate or severe impairment of attention. Subsequent treatment for the apnoea led to substantial improvements in attention scores for 60 per cent of these individuals - suggesting that for this sub group, at least, the sleep apnoea caused the difficulties with attention.

Likewise, in an analysis of 83 children with ADHD, David Gozal from the University of Louisville, Kentucky, and colleagues found that a quarter of those diagnosed with mild ADHD suffered from sleep apnoea, compared with just 5 per cent of those with strong ADHD and 5 per cent of healthy controls. "SDB can lead to mild ADHD-like behaviours that can be readily misperceived and potentially delay the diagnosis and appropriate treatment," the team concluded (Pediatrics, 2007, vol 111, p 554). What's more, a study of children undergoing surgery to remove their tonsils and adenoids (a common treatment for snoring and sleep apnoea) found that before the operation, one-quarter had a diagnosis of ADHD compared to 7.4 per cent of healthy controls. But a year after the operations, half of these children no longer met the criteria for ADHD (Archives of Otolaryngology - Head & Neck Surgery, vol 133, p 974). Mark Kohler from the Women's and Children's Hospital in Adelaide, Australia, who has studied links between ADHD and sleep, suspects that some children are being treated with drugs such as Ritalin while their true problem, a sleep disorder, goes unrecognised.
Some children are being treated with drugs such as Ritalin while their true problem, a sleep disorder, goes unrecognised

So how does poor sleep lead to behavioural and psychological problems? Some of the links are apparent. For example, every parent knows that tired children usually become hyperactive rather than sleepy. Sleep disruption also bumps up stress hormone levels, which could contribute to daytime anxiety, a component of many psychiatric disorders. More intriguingly, it now seems sleep disruption can fundamentally interfere with the brain's ability to process emotion and to react to an emotional stimulus in an appropriate way (see "Feeling emotional? Take a nap").

While it is common knowledge anecdotally that a poor night's sleep is likely to make you more irritable the next day, Walker and his colleagues uncovered key evidence for why this should be so. The team showed a set of increasingly disturbing images to people who had slept normally and people deprived of sleep for 35 hours. In the sleep-deprived group, the gruesome images produced 60 per cent more activity in the amygdala - a primitive, emotionally reactive part of the brain - than in well-rested people. Further scans revealed that in those deprived of sleep the amygdala was failing to communicate with the prefrontal lobe, which normally controls and sends inhibitory signals down to the emotional brain. "The reason we don't blow our top when someone says something we don't like is because we have a highly developed prefrontal cortex, which acts as an emotional brake," says Walker. A loss of communication between the amygdala and the prefrontal lobe is one way that sleep loss could create psychiatric symptoms, he thinks. "In a number of psychiatric disorders, such as depression, it has been demonstrated that the frontal lobe's activity becomes disrupted. There's also preliminary evidence [of this] for ADHD and post-traumatic stress disorder," Walker says.

In another strand of research, evidence is growing that sleep - and dreaming, REM sleep, in particular - helps the brain to process memories. Disrupt this mechanism, and you could end up with psychological problems such as PTSD.

In August 2008, Stickgold and colleagues reported that when people are presented with pictures of an emotional or neutral object or scene, their memory for these scenes decreases during the day. After a night's sleep, they forget pretty much everything except the things that roused their emotions, for which their memories stay the same, or even improve (Psychological Science, vol 19, p 781). Cast your mind back, says Walker, and you will appreciate that almost all of your memories are emotional ones. He thinks this is because emotions act as a red flag for important things that we should be remembering. But, crucially, if you recall them now you don't re-experience the visceral reaction that you had at the time. Somehow, the brain has retained the memory while stripping away the visceral emotion. Both Stickgold and Walker believe this stripping process occurs during REM sleep.

They note that during REM, production of serotonin and noradrenalin shuts down in the brain. Noradrenalin is the neurochemical associated with stress, fear and the flight response; it translates to adrenalin in the body. Serotonin modulates anger and aggression. "You get this beautiful biological theatre during REM sleep, where the brain can go back over experiences it has learned in days past, but can do so in a situation where there are none of these hyping-up neurochemicals," Walker says. So although dreams can be highly emotional, he thinks that they gradually erode the emotional edges of memories.

In PTSD this process seems to fail, so that traumatic memories are recalled in all their emotional detail. It is not clear yet why this happens, but there is evidence that people with PTSD have higher waking levels of noradrenalin and serotonin. This might mean that neurotransmitters cannot be damped down sufficiently during REM sleep for the emotional intensity of the memories to be stripped away, says Walker.

Clearly there is still a lot of work to be done in untangling the ways in which sleep disruption might create psychiatric symptoms. Among the anomalies that need explaining is the fact that antidepressant medications reduce REM sleep and yet can be very effective. Then there is the puzzling finding that many people with depression say they feel happier after a night deprived of sleep (Biological Psychiatry, vol 149, p 471).

Nevertheless, when it comes to exactly how and to what extent sleep disorders could be responsible for psychiatric problems, Walker says: "We're getting there. Five years ago, that question wasn't on the radar for anyone - scientists or lay people. The fact that we're aware of it now and asking those questions means it's inevitable we'll find out."

Read our related editorial: Restless or unrested?
Feeling emotional? Take a nap

If you find your working relationships deteriorate as the day wears on, take a nap. In a study yet to be published, Matt Walker from the University of California, Berkeley, and colleagues showed people pictures of faces expressing different emotions, including fear, anger, sadness and happiness, and asked them to rate how emotional they thought these faces were. They did this at midday and again at 6 pm. Participants were significantly more sensitive to angry and fearful faces at the second session.

However, this change did not happen if volunteers were allowed a 90-minute lunchtime nap during which they managed to achieve REM sleep. What's more, these people also became more receptive to happy faces. Walker concludes that REM sleep refreshes our civilising emotional reactions. "Sleep is essentially changing the magnetic north of your emotional compass, in a good way," he says.
When is asleep not asleep?

When people say they feel half-asleep they could be right.

Traditional models of sleep involve a top-down control centre that tells the entire brain when it's time to doze off. But last year, James Krueger of Washington State University in Pullman argued that parts of the brain fall asleep independently, and what we call the state of "sleep" only occurs when enough parts "drop off" to change our state of consciousness (Nature Reviews Neuroscience, vol 9, p 910).

He and his colleagues believe sleep starts in individual cortical columns - assemblies of neurons that are thought to be a basic processing unit of the brain - which become tired as a result of use. Only later is it consolidated by central mechanisms.

This insight could explain disorders such as sleepwalking, where it is possible to negotiate objects yet be unaware of your actions, and "sleep inertia", the first drowsy half-hour or so after waking up. "It is easy to envision an explanation for these phenomena by imagining parts of the brain awake and parts being asleep simultaneously," says Krueger.

Although sleep researchers have not been very receptive to the idea, he believes a big rethink is called for. "In my opinion, the textbooks should be rewritten."

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
This may be good news for longevity aspirants.



New Scientist


SCIENCE IN SOCIETY


Mole rats may hold secret to long life

* 23 February 2009
* Magazine issue 2696. Subscribe and get 4 free issues.
* For similar stories, visit the Death Topic Guide

THEY may not be the prettiest creatures, but naked mole rats may hold the secret to longevity. They can live for nearly 30 years longer than any other rodent.

Ageing is often blamed on the oxidising compounds we produce in our bodies, which gradually wear down DNA and proteins. These damaged molecules then go on to wreak havoc in cells.

Yet ageing naked mole rats have similar levels of oxidants to mice that live to be just 3½. To investigate, Rochelle Buffenstein of the University of Texas Health Science Center in San Antonio and colleagues extracted liver tissue from both species and treated it with chemicals that "unravel" proteins to reveal damage. They found twice as many undamaged proteins in naked mole rats as in mice. What's more, the rats' protein recycling machinery was exceptionally active (Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.0809620106).

The team suspects that naked mole rats manufacture extra quantities of molecules that are responsible for labelling damaged proteins that need to be recycled quickly to minimise their effect on cells. The researchers hope to identify these molecules and test if it is possible to use them to treat age-related disease in humans.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
To any parent with small children allergies provide a lot of angst, here is an update on peanut allergy.
)
Childhood peanut allergy rate doubles

By Dani Cooper for ABC Science Online

Posted 3 hours 21 minutes ago
Updated 2 hours 47 minutes ago


The study found there is growing evidence that guidelines promoting peanut avoidance in young diets may be counterproductive. (ABC News: Giulio Saggin, file photo)

* Related Story: Doctors one step closer to peanut allergy cure

The incidence of peanut allergy among Australian toddlers has doubled in the past nine years, a new study suggests.

The study of children living in the Australian Capital Territory reports the increase has come despite increased efforts by parents to avoid giving toddlers peanuts in their diet.

Co-author Dr Raymond Mullins, an allergy expert at the John James Medical Centre, says the findings highlight the need to invest heavily in research to understand what has led to the allergy epidemic of the past decade.

And, he says, it adds to growing evidence that guidelines promoting peanut avoidance in young diets may be counterproductive.

For the study, Dr Mullins and colleagues at the University of Melbourne and Australian National University looked at the characteristics of 778 peanut allergy sufferers aged from four months to 66 years across a 13-year period.

The retrospective study, published online in the Journal of Allergy and Clinical Immunology, found no differences in age of onset, sex distribution, severity of reaction or age of first reaction during that period.

However, the incidence of peanut allergy by age 72 months for children born in 2004 was double that for those born just four years earlier in 2001.

Dr Mullins says the Australian findings match data from the US and UK that shows peanut allergy prevalence is also on the rise in those countries.

Generation allergy

He says the increase in children with the condition will lead to increasing health costs to the nation as what he terms Gen-A (generation allergy) matures into teenagers and adults.

Dr Mullins says the study rejects suggestions that the increase in allergies is the result of over-anxious parents.

"The fact that severity did not change undermines the community perception that the increase is the result of anxious parents presenting with milder cases. The increase is real, and for 80 per cent of those affected, they will still be allergic for decades to come" Dr Mullins said.

Dr Mullins says there is a growing body of thought that avoidance is the wrong strategy to combat peanut allergy.

He says a study published in the November edition of the Journal of Allergy and Clinical Immunology compared peanut allergy rates of Jewish children living in Israel and in the UK.

The study showed that Israeli children eat an average 7.8 grams of peanuts per month from eight to 14 months of age, while the UK children averaged 0 grams.

But the rate of peanut allergy among the UK toddlers was 10 times higher than in the Israeli children.

Last weekend British researchers revealed they had been able to build tolerance for peanuts in children who normally had a severe reaction to the food.

The researchers gave small daily doses of peanut flour to children with a severe peanut allergy to help them build tolerance to the nuts during a six-month period.

By the end of the trial, the researchers had determined that eating 12 nuts a day did not lead the children to have a life-threatening reaction in the form of anaphylaxis.

More research needed

Dr Mullins says his team's study highlights the need for more funding to be directed at understanding the cause of the increase.

"There is more evidence about what food allergy is not due to then what it is," he said.

Among the factors that have been discounted are a mother's diet during pregnancy and breastfeeding, genetically modified food, additives and preservatives in food.

"The proteins triggering allergic reactions are the same ones that did so when Moses was a kid," he said.

He also says the too-clean hygiene theory has also been targeted as a candidate, but this has yet to be studied in detail.

There is also some evidence emerging that Vitamin D deficiency may play a role.

Dr Mullins says the five-year Leap Study currently under way at Evelina Children's Hospital in the UK, is a controlled study comparing avoidance with early introduction of peanuts with the risk of a peanut allergy developing.

He says its results will help determine if the "public health measures to avoid or delay exposure to allergenic food ... might have in part contributed" to the increase in peanut allergies.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Science Readers,


Ethical stem cells stripped of 'cancer' genes

* 18:00 01 March 2009 by Peter Aldhous
* For similar stories, visit the Cancer , Stem Cells and Genetics Topic Guides

Through a neat genetic trick, it is now possible to create "reprogrammed" stem cells that have been stripped of potentially cancer-causing genes. This latest advance boosts hopes of one day using these cells to treat devastating human diseases.

The reprogramming technique was originally developed by Shinya Yamanaka of Kyoto University in Japan, who used retroviruses to insert four genes into the chromosomes of mouse and human skin cells.

Together, these genes turned back the cells' developmental clock. The resulting "induced pluripotent stem cells", or iPS cells, had essentially been turned into embryonic stem cells, able to turn into any of the body's tissues. Unlike previous sources of ESCs, the cells had not required the use of a human embryo, so gets around ethical concerns.

But Yamanaka's method creates a two-pronged risk of cancer. Not only can retroviruses jump into and disrupt genes that normally hold cancer in check, but the genes used for reprogramming can themselves trigger tumours.
Cut and paste

Until now, most scientists trying to create safer iPS cells have tried to avoid inserting the reprogramming genes into the chromosomes in the first place.

Last year, for instance, a team led by Konrad Hochedlinger of the Massachusetts General Hospital in Boston put the reprogramming genes into adenoviruses, which live for only a short while in a cell and don't normally jump into its chromosomes. The technique worked in mouse liver cells – but was very inefficient.

Now two groups of researchers have taken a different approach, using a system that puts the genes into chromosomes, but allows them to subsequently be removed.

Rather than using viruses, the researchers instead turned to a "transposable element" known as piggyBac. Originally found in insects, piggyBac is a parasitic stretch of DNA that can move around the genome, cutting and pasting itself into a chromosome where the genetic sequence reads "TTAA".

The two teams, led by Keisuke Kaji of the University of Edinburgh, UK, and Andras Nagy of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto, Canada, removed the gene for piggyBac's cut-and-paste enzyme and instead packed the element with the four reprogramming genes.

When the altered piggyBac was then put into mouse and human skin cells together with a separate loop of DNA bearing the gene for the cut-and-paste enzyme, it jumped into the chromosomes and turned them into iPS cells with about the same efficiency as Yamanaka's retroviruses.
Gene eraser

The key advance, however, is that a flaw in piggyBac's machinery makes it possible to remove the element and its cargo of potentially cancer-triggering genes after it has triggered reprogramming.

Each time piggyBac leaps out of the genome, it has only a 40% chance of reinserting itself. By taking the iPS cells and reactivating the element, the researchers were able to get piggyBac to jump out of the chromosomes and then screen for those cells in which it had failed to jump back in again. This left them with chromosomes free of the dangerous reprogramming genes. "Not even a partial sequence was left," says Nagy.

"This is an elegant method," says Arnold Kriegstein, who heads the Institute for Regeneration Medicine at the University of California, San Francisco. "It allows you to seamlessly excise the genes."

Whether the method catches on may depend whether on rival researchers succeed in attempts to devise simpler methods that don't require the reprogramming genes. For instance, Sheng Ding of the Scripps Research Institute in La Jolla, California, is experimenting with reprogramming using small-molecule drugs.

Journal reference: Nature (DOI: 10.1038/nature07863 and DOI: 10.1038/nature07864)

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Science Readers,

It looks like a simple constituent of vegetable oil and deodorants (Glycerol Monolaurate) can block the inflammation of Aids and once you kill the inflammation you have killed the virus.


New Scientist


Home |Health |Life | News
Kill the inflammation, kill the HIV?

* 08 March 2009 by Debora MacKenzie
* Magazine issue 2698. Subscribe and get 4 free issues.
* For similar stories, visit the HIV and AIDS Topic Guide

WE don't yet know why HIV spreads to women so much more readily in Africa than elsewhere, but African women desperately need protection from the virus during sex. Now a cheap and relatively safe chemical that damps down vaginal inflammation may do just that.

Ashley Haase and colleagues at the University of Minnesota in Minneapolis have discovered that a few epithelial cells on the cervix of female macaques are the first point of entry for SIV, the monkey equivalent of HIV. Nearby immune cells respond by emitting molecules that trigger inflammation and summon T-cells to the cervix. These would normally destroy invaders but T-cells happen to be the very cells SIV (and HIV) use to infect their new host.

Studies of toxic shock syndrome, a life-threatening bacterial infection that can affect women using tampons, had already identified chemicals that can suppress vaginal inflammation, including glycerol monolaurate, a constituent of vegetable oils used widely in food and deodorants.

When Haase's team mixed glycerol monolaurate with vaginal lubricant, and applied it to the vaginas of five macaques, they found that the animals resisted infection even after repeated exposure to SIV. It seems the chemical blocked the immune reaction that summons the T-cells to the cervix (Nature, DOI: 10.1038/nature07831).

It is not yet clear whether glycerol monolaurate would block HIV in a woman's cervix already inflamed by other infections, or whether blocking cervical immune responses might leave her less protected from other infections. But the team argues that even if the gel - which costs less than a cent a dose - is only 60 per cent effective, it would prevent nearly a million infections a year, and might slow the heterosexual transmission of HIV in Africa.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi,
Another study has shown problems with excessive red meat consumption only this time it is linked to macular degeneration.


Too much red meat leads to vision loss: study

Posted 1 hour 27 minutes ago

A link has been found between eating too much red meat and vision loss.

Researchers from the Royal Victorian Eye and Ear Hospital have found people who eat red meat more than 10 times a week experience increased macular degeneration, leading to vision loss.

The link was stronger for people who ate high levels of salami and continental sausage, but weaker for people who ate more chicken.

Report author Dr Elaine Chong it shows people should be aware of how much red meat they eat.

"Everything in moderation is the answer," she said.

"I guess when looking at the study we actually found that a quarter of the study population ate more than 10 serves of red meat a week which is quite substantial ... it's also like two serves of red meat a day," she said.

"What we found was that excessive meat intake - more than 10 serves of red meat per week - was associated with about a 47 per cent increased association of early and late macular degeneration."

Tags: health, diet-and-nutrition, medical-research, australia

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
This is good news for Parkinson sufferers.

How deep brain stimulation works for Parkinson's
Finding that nerve fibers are where changes may happen could enable less-invasive treatments
By Tina Hesman Saey
Web edition : 1:18 pm
font_down font_up Text Size
access
Enlargemagnify
FROM SPINE TO BRAINShown is a recording of the brain activity of a rat with Parkinson's symptoms before (above) and after (below) spinal cord electrical stimulation.IMAGE CREDIT: Fuentes

View a video about this research.

Getting a move on is difficult for people with Parkinson’s disease. Deep brain stimulation has helped restore movement for some patients, but no one was sure exactly how the technique worked.

Now two studies reveal the brain circuitry involved and suggest possible alternatives to the highly invasive surgery.

“Deep brain stimulation is basically a black box,” says Guoping Feng, a neurobiologist at Duke University in Durham, N.C. Scientists know that inserting an electrical probe deep into the brain and stimulating an area known as the subthalamic nucleus can help people with Parkinson’s disease overcome the disorder’s neurological block on movement.

But much controversy surrounds the mechanism by which the stimulation works. Some researchers think the technique stimulates neurons that initiate movement. Others say it blocks inhibitory neurons, allowing brain signals to resume. And yet another theory holds that it influences the flow of information along axons — fibers that connect neurons to each other.

A study published online March 19 in Science shows that deep brain stimulation exerts its effect on axons, specifically those that feed into the subthalamic nucleus, rather than on the neurons in the structure.
access
Enlargemagnify
LIGHT THERAPYUsing a new technique called optogenetics, Stanford University researchers used light-activated proteins with fiber optics to help mice with Parkinson’s-like symptoms move more easily and quickly. The line on the left shows the path of an untreated animal and the line on the right shows the path of a treated animal.Image courtesy of K. Deisseroth

Stanford University researchers led by Karl Deisseroth used light-triggered molecules to turn on and off neurons in the deep brain structure in mice. The team employed the new molecular technique, developed to map neural circuits, to simulate the effect of deep brain stimulation. In a separate paper appearing in the March 19 Nature, Deisseroth and his colleagues show that these light-activated molecules can also be used to investigate biochemical processes in other cells in the body.

For the Science study, the team genetically engineered mice that have a condition that mimics Parkinson’s disease to produce light-responsive proteins only in certain cells in the brain. Then, the researchers inserted fiber optic threads into the mice’s brains. The team used a pulse of blue laser light to increase activity of the cells, or a burst of yellow laser light to quiet the cells. The scientists also used electrical probes to measure activity of the neurons.

When the researchers turned on the light in cells in the subthalamic nucleus nothing happened. But light stimulation of incoming axons improved the mice’s movements. Quieting activity of the axons made the movement disorder worse.

These axons are extensions of neurons located in the brain’s motor cortex, a region that controls movement. The cortex is the outer part of the brain and has six layers. Cells in layer V control the motor symptoms, the team reports. The finding suggests that less invasive procedures to stimulate parts of the brain closer to the surface might be an alternative to deep brain surgery.

“This is a big change in the way we look at the circuit,” says Romulo Fuentes, a neurophysiologist at Duke University.

Fuentes and his colleagues report in another study in the March 20 Science that a less invasive surgery might also relieve Parkinson’s disease symptoms. The researchers found that stimulating the spinal cord could restore movement to rats and mice with Parkinson’s–like problems. Deisseroth speculates that the neurons in layer V might form a bridge between the spinal cord and the deeper layers of the brain.

Spinal cord stimulation is already used in people to help alleviate chronic pain, so researchers may eventually be able to adapt the technique to treat Parkinson’s disease in people, Fuentes says.

“It’s good news for patients,” says Feng, who was not involved in either study. “Of course, it is not a cure.”

He says that the light-responsive techniques may help uncover the neural circuitry that leads to other psychiatric diseases, such as depression and obsessive-compulsive disorder, which are also sometimes treated with brain stimulation. And spinal cord stimulation or other minimally invasive therapies may offer psychiatric patients an alternative to deep brain surgery.

Researchers at Duke University Medical Center have developed a novel stimulation method, the first potential therapy to target the spinal cord instead of the brain, which may offer an effective and less invasive approach for Parkinson's disease treatment.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi science watchers,
A new treatment for blood pressure may have arrived.


ScienceDaily: Your source for the latest research news and science breakthroughs -- updated daily
Science News
Share Blog Cite
Print Email Bookmark
Proteins From Garden Pea May Help Fight High Blood Pressure, Kidney Disease

ScienceDaily (Mar. 22, 2009) — Researchers in Canada are reporting that proteins found in a common garden pea show promise as a natural food additive or new dietary supplement for fighting high blood pressure and chronic kidney disease (CKD). Those potentially life-threatening conditions affect millions of people worldwide.
See also:
Health & Medicine

* Kidney Disease
* Hypertension
* Cholesterol

Plants & Animals

* Food
* Cell Biology
* Molecular Biology

Reference

* Inflammation of the kidney
* Dialysis
* Kidney transplantation
* Excretory system

The study, which was presented March 22 at the American Chemical Society's 237th National Meeting, is the first reporting that a natural food product can relieve symptoms of CKD, the scientists say.

Peas long have been recognized as nutritional superstars, with healthful amounts of protein, dietary fiber, and vitamins wrapped in a low-fat, cholesterol-free package. The new research focuses on the yellow garden pea, a mainstay pea variety enjoyed as a veggie side-dish and used as an ingredient in dozens of recipes around the world.

"In people with high blood pressure, our protein could potentially delay or prevent the onset of kidney damage," says study presenter Rotimi Aluko, Ph.D., a food chemist at the University of Manitoba in Winnipeg, Canada. "In people who already have kidney disease, our protein may help them maintain normal blood pressure levels so they can live longer."

High blood pressure, or hypertension, is a major risk factor for CKD, a condition that has been affecting an increasing number of people in the United States and other countries. Estimates suggest that 13 percent of American adults — about 26 million people — have chronic kidney disease, up from 10 percent, or about 20 million people, in the 1990s. CKD is difficult to treat, and may progress to end-stage kidney disease that requires kidney dialysis or a kidney transplant. That situation is fostering a search for new ways of treating CKD and preserving kidney function.

Working with University of Manitoba colleague Harold Aukema, Ph.D., Aluko purified a mixture of small proteins — called pea protein hydrolysate — from the yellow garden pea. The researchers fed small daily doses of the protein mixture to laboratory rats with polycystic kidney disease, a severe form of kidney disease used as a model for research on CKD. At the end of the 8-week-long study period, the protein-fed rats with kidney disease showed a 20 percent drop in blood pressure when compared to diseased rats on a normal diet, the researchers say.

"This is significant because a majority of CKD patients actually die from cardiovascular complications that arise from the high blood pressure associated with kidney malfunction," Aluko notes.

In both rats and humans with polycystic kidney disease, the condition causes urine output to be severely reduced and the kidneys are unable to properly remove dangerous toxins. The researchers showed that their pea extract caused a 30 percent boost in urine production in the diseased rats, bringing their urine to within normal levels.

"That's a huge improvement," says Aluko, adding that there were no obvious adverse side effects from the pea protein.

Based on those promising results, the researchers plan to test the protein extract in humans with mild hypertension within the next year at the Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, in collaboration with co-investigator Dr. Peter Jones. Scientists do not know exactly how the pea extract works. However, it appears to boost production of cyclooxygenase-1 (COX-1), a protein that boosts kidney function, the researchers say.

Aluko points out that eating yellow peas in their natural state won't produce the same potential health benefits as the purified protein extract. The potentially beneficial proteins exist in an inactive state in natural peas, and must be activated by treatment with special enzymes.

But the pea extract does have a very welcome social advantage over fresh peas: "It won't give you gas," notes Aluko. That's because the purified proteins don't contain the complex plant-sugars found in fresh beans that are known to trigger flatulence. The extract itself does not appear to have any unpleasant taste or odor, he adds.

If studies continue to show promise, Aluko estimates that the extract could hit the consumer market within the next two to three years. The extract could be made into a soluble powder that can be added to foods and beverages or it could be developed into a pill, the scientists say.

The government of Canada funded the research through its Advanced Foods and Materials Network of Centre of Excellence (AFMnet), whose scientific director is Dr. Rickey Yada and executive director is Ron Woznow. Nutri-Pea Ltd., a private Canadian company that specializes in making food products from yellow peas, was the industrial partner for the project.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif

Hi,
This might help explain the plight of African Americans and high blood pressure.


ScienceDaily: Your source for the latest research news and science breakthroughs -- updated daily
Science News
Share Blog Cite
Print Email Bookmark
Hormone Linked To High Blood Pressure And Blood Vessel Disease In African-Americans

ScienceDaily (Feb. 26, 2009) — Researchers at The Medical College of Wisconsin in Milwaukee have linked higher levels of the hormone aldosterone to high blood pressure and blood vessel disease in African Americans. Aldosterone is secreted by the adrenal glands and causes salt retention by the kidneys.
See also:
Health & Medicine

* Hypertension
* Heart Disease
* Kidney Disease
* Lung Cancer
* Cholesterol
* Prostate Cancer

Reference

* Blood pressure
* Electrolyte
* Excretory system
* Blood sugar

The study appeared in the December 18, 2008, American Journal of Hypertension.

"The prevalence of high blood pressure, or hypertension, in African Americans is among the highest in the world," says lead researcher Theodore Kotchen, M.D., professor of medicine and associate dean for clinical research.

"Previously, we found relatively high aldosterone levels in African Americans with high blood pressure," he said. "In this study we have found that aldosterone may not only contribute to high blood pressure but also to related changes in blood vessel function in the kidneys and extremities."

The researchers compared 24-hour blood pressures, heart output, blood vessel stiffness, kidney blood flow, and aldosterone levels in 224 African Americans with high blood pressure, with those of 217 African Americans with normal blood pressure.

They found that those with high blood pressure had higher levels of aldosterone. Their heart output was lower, extremity blood vessel stiffness was greater, kidney blood flow was lower, and kidney resistance to blood flow was higher than those with normal blood pressure.

Most importantly, the blood pressure levels, blood vessel flexibility, and kidney blood flow in those with high blood pressure were all directly correlated with their aldosterone levels.

"These observations suggest that aldosterone contributes to high blood pressure and its related heart, kidney, and blood vessel disease in African Americans," says Dr. Kotchen.

His research has been continuously funded by the National Institutes of Health's National Heart, Lung and Blood Institute for over a decade.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
julie1969
Desesitization seems to be a trend in allergy research. With exposure to tiny amounts to build up tolerance. There have been a number of studies on the subject of late. Word of warning do not try this without medical supervision. The small amounts of powder is ground very fine and can not be replicated at home so do not even think of it. That being said results have been good

http://www.google.com/hostednews/canadianp...nYiKi6jYCRBgK7g
John Bobbin BNat
Hi Readers,
This is a very unlikely source of treatment, I wonder where the inspiration came from to do this experiment?


Fart molecule could be next Viagra

* 06 March 2009
* Magazine issue 2698. Subscribe and get 4 free issues.

THE stink of flatulence and rotten eggs could provide a surprising lift for men. Hydrogen sulphide (H2S) causes erections in rats and may one day provide an alternative to Viagra for men.

The penis is packed with spongy tissue that produces an erection when it fills with blood. Nitric oxide (NO) helps relax the walls of arteries that supply the penis, allowing extra blood to flow in. Viagra works by blocking an enzyme that destroys NO.

H2S has recently been shown to relax the walls of major blood vessels too. Now Giuseppe Cirino at the University of Naples Federico II in Italy and his colleagues have found enzymes that produce H2S in human penile tissue. Injecting this tissue with H2S dilated the blood vessels, while injecting it into the penises of live rats produced erections (Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.0807974105).

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,
I wonder do thrill seekers go to natural therapists and fall for glib talking salesmen/women (I think there are more women). Placebo response has interested scientists for a very long time, why should it be so high in some experiments and not in others, this article from New Scientist might help explain it.


Home |Health | News
Thrill-seekers could explain placebo mystery

* 22:00 14 April 2009 by Ewen Callaway
* For similar stories, visit the The Human Brain Topic Guide

If rollercoasters and rock concerts sound fun but leave you with a headache, a drug-free sugar pill might be all that's needed to soothe you.

Thrill-seekers enjoy a stronger placebo response than people with more restrained personalities, new research shows.

It's too early to prescribe phoney pain treatments based on personality tests, says neuroscientist Petra Schweinhardt, of McGill University in Montreal, whose team tested 22 male university students. But if confirmed in larger trials, her team's findings could help pharmaceutical companies avoid testing experimental drugs on people with strong placebo responses, she says.

Her team injected a pain-inducing saline solution into the left and right legs of willing volunteers for 20 minutes. "It's a dull pain, a dumb pain, it's aching, it's annoying," she says.

Before the injection, her team told volunteers they were testing an experimental analgesic cream – really just skin lotion. To make the rouse more believable, researchers said they would test one leg with the treatment and one leg with a non-medicated lotion.
Pain relief

"We really told them the whole story in order to counteract any doubts in the treatment," Schweinhardt says.

Volunteers then rated their pain across both trials, and the difference amounted to the placebo response.

Not everyone got pain relief from the placebo, but those that did scored higher on tests that gauge sensation-seeking personalities. These characteristics explained about a third of the differences in placebo responses between volunteers.

"The fact that they show a pretty strong correlation between a personality trait and strength of placebo response, I do find interesting," says Jon Stoessl, a neurologist at the University of British Columbia, who has studied placebo response in patients with Parkinson's disease.

But he notes that a person's placebo response can change over time and varies depending on the condition, so personality alone probably won't explain his or her response.

"If whatever condition you're suffering from is severe on one occasion and really a minor nuisance on another occasion, that could affect the degree of placebo response," he says.
Pain seekers?

Schweinhardt agrees that motivation could play an important role in the placebo response. The personality traits that predicted placebo response are also linked to a brain chemical involved in valuing rewards, called dopamine.

If pain relief is a reward, then people more sensitive to dopamine might respond better to a placebo treatment than people who get less of a kick out of the neurotransmitter.

Paul Enck, a neuroscientist at the University of Tübingen in Germany, says this is the first study to conclusively link personality traits and placebo response. But he wonders whether students who sign up for a pain experiment are more likely to seek out new experiences than others.

"I would guess that at least some of these personality traits assess why people participated in this study," he says. "People like to be paid for something they enjoy rather than something they do not."

Journal reference: The Journal of Neuroscience DOI: 10.1523/jneurosci.5634-08.2009

Cheers biggrin.gif dry.gif sad.gif unsure.gif cool.gif
John Bobbin BNat
Hi Readers,
This is wonderful research, by using harmless bacteria they can control, scientists should be able to target any part of the body, think of all the uses for this, wow.


New Scientist

Home |Tech |Health | News
Bacteria take fantastic voyage through bloodstream

* 18:28 03 May 2009 by Colin Barras
* For similar stories, visit the Nanotechnology Topic Guide

Video: See bacteria being guided by magnetic fields

Canadian engineers have sent swimming magnetic bacteria through the bloodstreams of rats. The work is a step towards the team's goal of harnessing them as drug mules steered through human bodies using magnetic fields.

Microscopic machines have proven attractive to medics trying to make treatments ever more targeted and less invasive than surgery. But although it is now possible to make micromachines from individual molecules, providing them with power is another matter.

Propulsion systems or even swimming motions that work at larger scales don't work when scaled down because of the treacly forces that dominate fluids at microscopic scales.

Sylvain Martel's team at the École Polytechnique de Montréal in Canada think tapping the skills of bacteria that have evolved to swim with ease at the microscopic scale is the best solution.
Speed demon

"Instead of trying to build a nanomachine it makes more sense to spend effort trying to control what nature provides," says Martel. He and his team are focusing on a bacterium dubbed MC-1 – a microbial speed demon that swims 10 times faster than most species and can travel at top speeds of 200 micrometres per second using its twirling flagella.

If MC-1 was to be loaded with a drug and given the ability to target a particular tissue it could provide a nimble addition to the medical arsenal.

Apart from speed, the bacterium has another property that makes it a perfect candidate for the role: each cell contains a chain of magnetic nanoparticles, allowing the bacteria to sense and swim along magnetic fields.
Remote control

By placing a patient inside an MRI machine it would be possible to create a magnetic field to steer the bacteria in any direction, towards targets just a few micrometres across, says Martel.

Martel says initial tests suggest the bacteria are not harmful – and generally not harmed – inside the body. His team injected a 50 microlitre solution containing some 50 million MC-1 bacteria into the bloodstream of rats, and found no adverse reaction.

"More work needs to be done, but it appears a sufficient quantity of these bacteria can be injected without causing toxicity," he told New Scientist. The bacteria naturally die after about 40 minutes in the blood, and would then be cleaned up by the immune system.

The initial rat trials simply assessed the health impact of injecting the bacteria – the next step is to guide them using magnetic fields, which will be precisely controlled via computer, says Martel. The team has already shown that's possible in principle by steering the magnetic bacteria in a 50-micrometre-diameter tube system (see movie).
Metal mules

In 2007, the same team piloted metal particles through the blood stream of a living pigMovie Camera using an MRI machines. Using magnetic bacteria is a more attractive option because the applied field needs only to direct the microbes as they propel themselves towards the target.

Bradley Nelson at the Swiss Federal Institute of Technology in Zurich, who earlier this year designed a magnetically controlled artificial bacteriumMovie Camera, thinks the work is an improvement on a 2004 study by Howard Berg at Harvard University.

Berg used another bacterial species to create a simple propulsion system. "By using MC-1 instead, Martel had been able to demonstrate steering in addition to propulsion," Nelson says. "I am sure there are issues in keeping the bacteria happy, but it is certainly a clever idea."

International Journal of Robotics Research (DOI: 10.1177/0278364908100924)

Great research don't you think.

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi,
I think you will find this very interesting.


First heartbeats trigger blood formation

* 19 May 2009 by Andy Coghlan
* Magazine issue 2708. Subscribe and get 4 free issues.

WHEN the embryonic heart begins to beat, it kick-starts the production of blood from cells lining the growing aorta, two independent research teams have shown.

As the heart starts pumping a primitive blood-like fluid around the body of an embryo, the change in pressure from the flowing liquid is the cue for cells lining the aorta to change first into blood stem cells, then into all blood-cell types in the body. As they multiply and mature, these rapidly replace the initial embryonic "blood", which is composed of embryonic red blood cells in a nutrient-rich serum.

Leonard Zon of the Howard Hughes Medical Institute in Boston and his colleagues demonstrated that the pressure of the embryonic fluid is what switches on the production of adult blood in zebra fish and mouse embryos. "The finding answers an age-old question as to why the aorta makes blood stem cells at all," says Zon, whose findings appear in Cell (DOI: 10.1016/j.cell.2009.04.023). "The answer is that there must be a cue to start making adult blood cells, and that cue is the onset of circulation and blood flow," he says.

The discovery could lead to a source of blood for people with leukaemia who need a transplant but don't have a matched donor, by exposing stem cells to flowing liquid, says Zon.

In a separate study, George Daley of the Children's Hospital Boston and colleagues found that blood cells form more readily in cultures of embryonic stem cells if they're exposed to fluids mimicking the usual flow and pressure of blood (Nature, DOI: 10.1038/nature08073). They also showed the phenomenon in embryonic aortic tissue from mice embryos engineered to have no heartbeat or circulation. Left alone, the aortic tissue made little blood, but blood production soared when Daley exposed the tissue to flowing fluid.

"The discovery underscores the critical importance of mechanical forces play in the development of blood and other functional tissue," says Robert Lanza, chief scientist at Advanced Cell Technology of Worcester, Massachus

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi,
This is interesting but note that it says "may help protect" not absolute protection.

GREY hair may be unwelcome, but the processes that produce it are now better understood and could be protecting us from cancer.

Cells called melanocytes produce the pigments that colour hair and their numbers are kept topped up by stem cells. Hair goes grey when the number of stem cells in hair follicles declines. Now Emi Nishimura of Tokyo Medical and Dental University in Japan and colleagues have found what causes this decline in mice.

When the researchers exposed mice to radiation and chemicals that harm DNA, damaged stem cells transformed permanently into melanocytes. This ultimately led to fewer melanocytes, as it meant there were fewer stem cells capable of topping up the melanocyte pool. The mice also went grey (Cell, vol 137, p 1088). Nishimura's team proposes that the same process leads to the reduction in stem cells in the follicles of older people, especially as DNA damage accumulates as we age.

David Fisher, a cancer researcher at Harvard Medical School, suggests such processes may help protect us from cancer, by discouraging the proliferation of stem cells with damaged DNA, which could pass on mutations. "One likely beneficial effect is the removal of potentially dangerous cells that may contain pre-cancerous capabilities," he says.

Cheers (May help protect not guarantee protection) biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi,
I found this particularly interesting, I hope you do too.


New Scientist
Health
Warning over 'superbug' risk from pets

* 17:59 23 June 2009 by Andy Coghlan

"Superbugs" originating in hospitals are now increasingly being found in cats and dogs, and in victims of bites.

Ironically, most animals probably acquired their infections originally from their owners. The bugs then easily spread between pets and household members.

The rise parallels the increasing abundance of community associated methacillin-resistant Staphylococcus aureus (CA-MRSA) over the past decade or so.

"Pet owners need to be aware of the potential for transmission of infections from their pets," says Richard Oehler of the University of South Florida College of Medicine in Tampa, who has reviewed reported cases of pet infection with MRSA.

"An increase of pet-associated infections has been documented in the literature and has paralleled the increase in human MRSA infections," he says.
Antibiotic resistant

The first case was reported in the UK in 1988, in a pet cat kept on a geriatric ward. 2006 saw the first report in pets of USA300, an emergent "community" strain of MRSA in the US. And, in the same year, researchers in Pennsylvania found that MRSA accounted for 35 per cent of 111 S. aureus samples originally taken from cats and dogs.

Oehler says that the strains pose a special risk because they're resistant to antibiotics, and so may be more difficult than usual to treat if they result from cat or dog bites. Severe infections occur in about 20 per cent of bites. Sepsis can be a severe complication of bite wounds.

Children are at special risk, especially boys aged five to nine who provoke animals without realising the dangers. Often, because they're shorter than adults, they receive severe bites to the face, neck or head, whereas adults are most often bitten on the hand.
'Serious consequences'

"Bite infections can result in serious consequences, but MRSA can produce serious infections independent of the method of exposure," warns Oehler.

One study found, for example, that MRSA often occurs in simple skin infections in pets, and can easily spread to owners.

In the wake of his findings, Oehler recommends measures to avoid infection. "Wash hands before and after pet contact, and be wary of dogs licking your face, any medical devices or open wounds," he says.

"Also, be aware of your pet's health status, and keep open wounds on yourself and your pet covered when you're in contact with each other," he says.
Human contact

Oehler says that further research is needed to establish how superbugs circulate to pets, but the most likely route is via the owners.

The US Centers for Disease Control in Atlanta, Georgia, agrees.

"Most MRSA in humans is acquired by direct contact with other humans," it said in a statement to New Scientist. "In most cases, MRSA in companion animals is a result of humans exposing the animals to MRSA, so pets can become colonised or infected with MRSA by contact with colonised or infected humans."

Journal reference: The Lancet (vol 9, p 439)

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers, blink.gif
I find this fascinating, who would have believed the skin could have detoxified a major poison in this manner, by introducing P450 enzymes (liver enzymes that detoxify poisons) into the skin... Wow. What else is the human body capable of?


Skin growths saved poisoned Ukrainian president

* 17:46 07 August 2009 by Andy Coghlan

Benign skin growths that erupted on the face of Ukrainian president Victor Yushchenko helped save his life after he was poisoned with dioxin five years ago.

That's the verdict of doctors who have treated and monitored Yushchenko since an unknown assassin made the attempt on his life by lacing his soup with dioxin during a dinner in Kiev on 5 September 2004.

It now turns out that the lumps that grew on his face and body as a result probably saved his life by isolating the dioxin away from his vital, internal organs. They also helped to detoxify the poison, known chemically as TCDD (2,3,7,8-tetrachlrodibenzo-p-dioxin), by producing powerful enzymes called cytochrome p450s that are normally confined to the liver.
'Detoxifying organ'

The growths are rearrangements of skin, created from skin stem cells. "A new organ was created out of normal structures of the skin, and the tissue expressed very high levels of dioxin-metabolizing enzymes," says Jean Saurat, the dermatologist heading the team which treated Yushchenko at the Swiss Centre for Human Applied Toxicology in Geneva. "They were made to detoxify the dioxin."

"A hamartoma is a new organisation of normal cells that simply organise themselves differently," says Saurat. "So skin can be regarded as a detoxifying organ," he says.

Saurat says that at the start of treatment, Yushchenko had concentrations of TCDD 50,000 times higher than those typically found in people.
Fat stores

Saurat declined to specify details of how his team treated Yushchenko, saying these will be disclosed in a forthcoming paper.

However, the study released this week reveals that the treatment involved the anti-obesity drug orlistat, and olestra, a zero-calorie, indigestible fat product developed but rejected for use in food because it absorbed vitamins on its way through the gut, and caused "anal leakage" in some consumers. Dioxin is known to be stored in fat. Saurat said Olestra was used early on, but was not the main component of the treatment.

By monitoring concentrations of dioxin in blood, fatty tissue, faeces, skin, urine and sweat, Saurat established that about 60 per cent of the dioxin was excreted unchanged, mainly in the faeces. It took about 15 months for half of the contaminant to be excreted.

"He's not completely clean yet, but we've got more than 95 per cent of it out now," says Saurat.

Measurements of 17 different types of dioxin showed that all except the TCDD were at concentrations expected in the general population, proving that he was poisoned with pure TCDD.
'Strong constitution'

Saurat says that if he'd died early on – before the skin lesions became apparent – the source of his poisoning may never have been known. He says that it was three months before he received treatment, and was only saved by his strong constitution.

"God knows what would've happened if we didn't treat him," says Saurat. "When he first came in, he was very, very ill, and he might have died from poisoning, but he excreted a lot of dioxin early on through vomiting and diarrhoea," he says.

The skin lesions are still there, but less severe. "His skin will still need special care," says Saurat, adding that the data from the case will be invaluable for treating and detecting milder cases of dioxin poisoning or contamination.

Journal reference: The Lancet (DOI: 10.1016/S0140-6736(09)60912-0)

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
John Bobbin BNat
Hi Readers,

One of the biggest problems cancer patients suffer is the very real fear of cancer returning, cancer metastasises and starts a new tumour somewhere else, the sloughed off cells are almost impossible to see, so finding and destroying them is a huge problem. Cancer stem cells seem to be the big problem and now they have found a drug that can destroy them, and least in animal and laboratory trials, safety may be another problem entirely.


Drug shows cancer stem cells not invulnerable

* 18:21 13 August 2009 by Ewen Callaway
* For similar stories, visit the Cancer Topic Guide

A promising new cancer drug targets and kills the pernicious tumour cells responsible for metastasis and relapse. It is far too early to test the drug, called salinomycin, in humans, but the findings offer hope that the so-called cancer stem cells will eventually prove vulnerable to treatment.

"It's been thought that these cells are responsible both for metastasis and for recurrence following anti-cancer therapy," says Piyush Gupta, a molecular biologist at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, who led the new study. "There's been a lot of evidence to suggest that cancer stem cells are resistant to a variety of cell-death-inducing agents."

Gupta's team found that salinomycin kills breast-cancer stem cells at least 100 times more effectively than another popular anti-cancer drug. And mice implanted with human breast-cancer cells and later treated with salinomycin showed fewer signs of metastases than mice given a standard cancer therapy.
Hard to find

One reason cancer stem cells have been hard to target with drugs is their rarity in tumours and in laboratory cancer-cell cultures. This makes it difficult to hunt for drugs that selectively kill the cells.

To sidestep this problem, Gupta and his colleague Tamer Onder, formerly of the Whitehead Institute for Biomedical Research, also in Cambridge, reprogrammed normal skin cells into cells with some of the properties of cancer stem cells. Like normal cancer stem cells, the reprogrammed cells proved impervious to chemotherapy.

Next, Gupta and Onder's team tested about 16,000 different drugs against the reprogrammed cells: 32 of those compounds killed the reprogrammed stem cells, but not normal skin cells. Of the 32, salinomycin proved one of the most effective and the easiest to obtain in large quantities, Gupta says.

Tests in laboratory-cultured human breast-cancer cells confirmed the drug's potency. Mice injected with human breast-cancer cells – a common model for the disease – developed fewer aggressive tumours when treated with salinomycin, compared with a commonly used anti-cancer drug called paclitaxel.
Next steps

Further experiments in animals are needed before even thinking of trying salinomycin in humans, Gupta says. The researchers tested the drug on genetically homogenous laboratory cultures, so it also remains to be seen whether it will have the same effect on tumour cells collected from living people.

Little is known about the drug's safety, or whether it would find its way through the bloodstream to human tumours.

Gupta says the significance of his team's result is proof that cancer stem cells aren't invincible to drugs. "They do have weaknesses and we've essentially shown an approach to find them systemically," he says.

Journal reference: Cell, 10.1016/j.cell.2009.06.034 (in press)

Cheers biggrin.gif biggrin.gif biggrin.gif biggrin.gif
This is a "lo-fi" version of our main content. To view the full version with more information, formatting and images, please click here.
Invision Power Board © 2001-2010 Invision Power Services, Inc.